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Abstract 
Background: ATP-sensitive potassium channels are ATP sensitive pores that 
are found in vascular smooth muscle cells and play an important role in 
regulating vascular function. They are also expressed in blood but their 
relationship with vascular function is unknown. This study aims to investigate 
the previously unknown relationship between levels of KATP channels in blood 
and vascular function in normal healthy subjects.  
Methods: Blood samples were obtained and vascular function was assessed by 
carrying out four non-invasive tests in 50 normal healthy subjects. The levels of 
KATP channels were determined by measuring levels of mRNA subunits, 
Kir6.1/SUR2B, using real time reverse transcription polymerase chain reaction 
(RT-PCR) test while vascular function was assessed using (i) iontophoresis with 
laser Doppler flowmetry (LDF); (ii) post-occlusive reactive hyperaemia test 
(PORH) in the skin microvessels; (iii) pulse wave analysis (PWA) for arterial 
stiffness and (iv) flow-mediated dilation (FMD) in the macrovessels.  
Results: This study showed that Kir6.1 but not SUR2B, mRNA can be detected 
in human blood.  In addition, acetylcholine (ACH) (r=-0.579, p<0.001, n=40) and 
PORH (r= 0.366 p=0.020, n=40) correlated with Kir6.1 mRNA levels. No 
correlation was noted in brachial artery FMD (r=0.181, p=0.264, n=40) with 
Kir6.1 mRNA levels. Further analysis demonstrated gender specific differences 
where males showed statistically significant correlation between Kir6.1 mRNA 
levels and ACH (r=-0.561, p=0.005, n=23) as well as PORH (r= 0.418, p= 
x 
 
0.047, n= 23) but in females significant correlation was only seen between 
Kir6.1 mRNA levels and ACH (r=-0.628, p=0.007, n=17) but not PORH.  
Conclusion: The mRNA Kir6.1subunit levels in blood showed significant 
relationship with microvascular function. However, further studies are required 
to investigate the differences in direction of correlation between ACH and Kir6.1 
mRNA levels (negative correlation) as well as PORH and Kir6.1 mRNA levels 
(positive correlation). Levels of KATP in blood could potentially be used as blood 
marker for vascular function in vivo.  
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CHAPTER 1 
1.1 Introduction 
Cardiovascular disease (CVD) remains the leading cause of morbidity and 
mortality among adults in the UK and worldwide. The common occurrence of 
CVD in the UK is of particular concern since it is recognised that patients with 
CVD tend to have impaired quality of life with loss of independence, ultimately 
resulting in adverse social and economic implications.  
While traditional risk factors for CVD are widely agreed as significant causes of 
CVD, numerous studies have demonstrated that abnormal CV risk factors are 
often absent in individuals who develop CVD. The National Cholesterol 
Education Program guidelines showed that among relatively young adults 
admitted into the hospital for acute myocardial infarction, their mean lipid levels 
were within the normal range and approximately 70% of these patients fell into 
the lowest CV risk categories (Cleeman and Grundy, 1997, Akosah et al., 
2003). These research observations suggest that clinically significant CVD can 
occur without the presence of prior established CVD risk factors. For this 
reason, researchers have devised CV risk estimation systems to aid the 
detection of subclinical CVD and are constantly in search for novel markers for 
early presymptomatic CVD. 
CV risk estimation systems/scores have been long developed and used by 
clinicians to assess and stratify CV risk in asymptomatic high-risk individuals 
who have not developed CVD. Nonetheless, it is generally agreed that there 
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exist limitations to CV risk estimation systems as they assume that all risk 
factors exert constant effects in all individuals of differing age. In addition, they 
are based on the assumption that different risk factors exert a similar “effect” 
which is not necessarily the case as it is recognised that certain combinations of 
risk factors may act synergistically leading to higher risks as the effect is more 
than additive (Faeh et al., 2013). In addition, serum markers such as total 
cholesterol (low density lipoprotein (LDL), high density lipoprotein (HDL) and 
triglycerides) and C-reactive protein have been used in the attempt to stratify 
CV risk (Reiner et al., 2011, Keavney, 2011). Nonetheless, although it is shown 
that serum markers have been associated with CV risks, they are not believed 
to provide reliable measures or to substantially improve sensitivity of CV risk 
detection to justify their use in clinical practice (Francisco et al., 2006). 
More recently, vascular function tests such as post-occlusive reactive 
hyperaemia (PORH) and flow-mediated dilatation (FMD) have been applied in 
CV risk assessment (Roustit and Cracowski, 2012, Peters et al., 2012). They 
have been shown to be reliable and can act as surrogate markers in predicting 
CV risks in asymptomatic individuals (Strain et. al, 2010, Peters et al. 2012). 
Despite its clinical relevance, these tests have their limitations. They are often 
technically demanding, time consuming and the reproducibility and quality of 
test results are to some extent dependent on the operator. This is particularly 
true for ultrasound assessment of FMD (Celermajer, 2008). Therefore, these 
tests are not generally used in the clinical setting but are used more extensively 
in the research arena. These techniques will be discussed in more detail under 
the “Assessment of vascular function in humans” in Chapter 4. 
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It is generally recognised that abnormalities in the vasculature play a key role in 
the pathophysiology of CVD. Given that vascular function evaluated in the 
peripheral vasculature has been shown to correlate with cardiovascular function 
(Kuvin et al., 2001) and is abnormal in patients at risk for CVD (Deanfield et al., 
2007), an effort to search for a novel marker to detect and identify 
presymptomatic or subclinical CVD has focused on the vasculature, particularly 
in easily accessible peripheral arteries such as the brachial and carotid arteries. 
The next section provides an outline of the proposed project followed by an 
overview of this thesis. 
1.2 Project description 
This project investigates the possibility of using the levels of ATP-sensitive 
potassium (KATP) channel in blood as an indicator of vascular function. Briefly, 
KATP channels has been shown to interact with a variety of endogenous and 
pharmacological vasodilators, such as calcitonin gene-related peptide, 
vasoactive intestinal polypeptide, prostacyclin and adenosine, which all exert 
their effects directly on the vasculature (Isomoto et al., 1997, Quayle et al., 
1997). They are known to be composed of the protein, Kir6.1 and SUR2B 
subunits (Standen et al., 1989, Clapp and Gurney, 1992, Beech et al., 1993) 
and under pathophysiological conditions and in disease states, these channels 
are activated and may play a pivotal role in regulating vascular function (Wang 
et al., 2003). In a preliminary study by Jovanovic and Du (unpublished), it has 
been shown in that KATP channels are expressed in blood cells of mice. This 
observation raises a very interesting question- can the levels of KATP channels 
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in blood be a reflection of those expressed on vascular smooth muscle cells 
(VSMCs), and if that is the case, can the levels of KATP channels in blood be a 
surrogate marker of vascular function? The general features, structure and 
function of KATP channels will be explored, in more detail in Chapter 3 but briefly 
the role of KATP channels can be explained as follows: KATP channels play an 
important role in coupling cell metabolism to membrane potential and are crucial 
in the physiology and pathophysiology of many tissues. They were first 
identified in cardiac myocytes (Noma, 1983, Trube and Hescheler, 1984) and 
subsequently in other tissues such as pancreatic β-cells (Ashcroft et al., 1984, 
Cook and Hales, 1984), skeletal muscle (Spruce et al., 1985, Spruce et al., 
1987), central neurones (Ashford et al., 1984, Ashford et al., 1988) and smooth 
muscles (Standen et al., 1989, Beech et al., 1993, Kajioka et al., 1991, 
Kamouchi and Kitamura, 1994) . In these tissues, they have the role to, 
respectively, shorten the duration of the action potential in cardiac myocytes 
(Noma, 1983), regulate insulin release in pancreatic β-cells (Cook and Hales, 
1984), regulate the excitability of skeletal muscle (Spruce et al., 1985), regulate 
neuronal excitability, regulate neurotransmitter release (Kawano et al., 2009) 
and control the tone of vascular smooth muscle (Standen et al., 1989). KATP 
channels expressed in the VSMCs are of particular interest in this project. 
1.3 Overview of thesis 
The thesis is organised as follows: Chapter 2 begins with a brief overview of the 
normal human vasculature which includes the structure and function of the 
endothelium and VSMCs.  This is followed by a discussion on the mechanisms 
involve in the regulation of vascular tone by VSMCs and the underlying 
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pharmacology involved in this vasoregulatory mechanism. The second part of 
Chapter 2 provides a summary of CVD and the importance of vascular 
dysfunction. Chapter 3 gives an overview of the general features of KATP 
channels and provides evidence of their involvement in controlling vascular 
tone. In Chapter 4, the different modalities available to assess vascular function, 
invasively and non-invasively, are summarised. The aim and objectives of this 
project are listed towards the end of Chapter 4. This is followed by Chapter 5 
explains the experimental setup for data acquisition. The statistical analysis 
used for interpreting the data collected is summarised at the end of Chapter 5. 
Chapter 6 shows the results of this project. The discussion about the findings in 
this project, the project limitations, conclusions and recommendations for future 
research are found in Chapter 7. 
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CHAPTER 2 
The Human Vasculature  
2.1 Background 
In this section, I will discuss the normal structure and function of the 
endothelium and the vascular smooth muscle. Both components form the wall 
of the blood vessel and plays a central role in regulating vascular function.  
2.1.1 The endothelium 
The endothelium was originally thought to be a passive, inert semipermeable 
barrier between the circulating blood and the vascular smooth muscle cells of 
the tunica media. However, over the last four decades, extensive research has 
shown that the endothelium is indeed a highly dynamic organ which involves 
actively and reactively in various vasoregulatory processes.  
Structure 
Structurally, the endothelium consists of a monolayer of flat cells which line the 
innermost layer of all blood vessels (Figure 2.1). In adults, the endothelium 
weighs approximately 1kg, comprises about 1X1013 cells and has a surface 
area between 1-7m2 (about 7-8 tennis courts) (Nematbakhsh et al., 2008). 
Individually, the endothelial cell has a length of between 25-50μm, a width of 
between 10-15μm and a depth of up to 5μm and has a large nucleus which 
often protrudes into the blood vessel lumen.  
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Figure 2.1 Schematic diagram of the layers of blood vessel wall. (Adapted from 
http://bme.ccny.cuny.edu/faculty/jtarbell/SMC%20images%20for%20web%20sit
e/vessel%20wall%20schematic.jpg (25-10-2013)) 
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Function 
In its strategic location i.e. at the interface between blood and vessel wall, the 
endothelium does not only act as a physical anatomical barrier but it also serves 
as a gate keeper against the effect of various cellular and neurohumoral 
mediators. As a key regulator of vascular homeostasis, the endothelium plays 
an important role in maintaining the balance between blood vessel 
vasodilatation and vasoconstriction by secreting various vasoactive agents such 
as nitric oxide (NO) and prostacyclin (vasodilators) as well as endothelin and 
platelet activating factor (vasoconstrictors) (Vita, 2011). The endothelium plays 
a crucial role in thrombogenesis by favoring aggregation of platelets and 
formation of clots through organised induction of procoagulant/prothrombotic 
factors and suppression of anticoagulant mechanisms and fibrinolysis by 
releasing tissue-type plasminogen activator and urokinase (Gross and Aird, 
2000). The endothelium also participates in the stimulation and inhibition of 
VSMC proliferation and migration (Sumpio et al., 2002). In addition, the 
endothelium directs and regulates inflammatory processes by expressing an 
array of adhesion molecules, such as inter-cellular adhesion molecule-1 (ICAM-
1), vascular cell adhesion molecule-1 (VCAM-1) and selectins which allow the 
binding of platelets, leukocytes and monocytes onto the endothelial surface 
(Sumpio et al., 2002). Furthermore, it proves to be an indispensible participant 
in infection, haemostasis and immune responses. In terms of vascular 
pharmacology, the endothelium mainly controls underlying vascular smooth 
musculature hence vascular tone via the L-arginine/NO/cyclic guanosine 
monophosphate (L-arginine/NO/cGMP) pathway.  In this pathway, nitric oxide 
(NO) is synthesised in the endothelial cells from L-arginine by the enzyme, 
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endothelial NO synthase (eNOS or NOS3) with the presence of important 
cofactors such as calmodulin (CAM) and tetrahydrobiopterin (BH4) etc. This 
signaling cascade is activated initially in response to blood flow shear stress or 
to receptor agonists such as acetylcholine, bradykinin and adenosine 
triphosphate (Figure 2.2). The endothelial-derived NO then diffuses directly into 
the adjacent VSMCs where it activates the enzyme soluble guanylate cyclase 
(sGC) which increases the intracellular concentrations of cGMP substantially 
from guanosine triphosphate (GTP). Sequentially, cGMP activates the cGMP-
dependent kinase I which in turn increases the open probability of Ca2+-
activated K+(BKCa)-channels, leading to membrane hyperpolarisation as a 
result of an efflux of K+ and relaxation of the VSCMs.  
 
Figure 2.2 The L-arginine/NO/cGMP pathway (cGMP- cyclic guanosine 3',5'-
monophosphate; eNOS- endothelial nitric oxide synthase; GC- guanylate 
cyclase; GTP- guanosine 5'-triphosphate; M- muscarinic receptor; NO- nitric 
oxide). 
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2.1.2 Vascular smooth muscle  
VSMCs are mechanically active effectors of the vasculature and can be found in 
all blood vessels except the capillaries. By contraction or relaxation, the VSMCs 
change the distensibility of the vasculature which consequently results in 
vasoconstriction and vasodilatation of the blood vessels. It is recognised that 
VSMCs are not only controlled by the autonomic nervous system, specifically 
the sympathetic nervous system, but are also regulated by neurohormonal 
mechanisms such as circulating catecholamines e.g. adrenaline and local 
mechanisms such as locally produced metabolites which act directly on the 
VSMCs (Table 1.1).  
Table 2.1 Mechanisms involved in regulating vascular tone (Golan et al., 2012). 
Mechanisms involved  Effect on VSMCs 
Autonomic nervous system Activation of α1-adrenergic receptors on VSMCs 
results in vasoconstriction whereas activation of 
β2-adrenergic receptors on VSMCs causes 
vasodilatation 
Neurohumoral 
mechanisms 
Circulating catecholamines secreted from the 
adrenal glands regulate vascular tone via α1-
adrenergic receptors and β2-adrenergic receptors 
on VSMCs. Other neurohumoral mediators include 
angiotensin II which acts on angiotensin II receptor 
subtype I leading to vasoconstriction of arterioles  
Local mechanisms Includes autoregulation of VSMCs (by 
vasoconstriction or vasodilatation) in response to 
changes in perfusion pressure and regulation of 
vascular tone by locally producing substances 
such as H+, CO2, O2 
 
11 
 
Structure  
VSMCs typically have a diameter of 5 to 10 µm and a length which varies from 
50 to 300µm. They make up the main stromal portion of the blood vessel wall 
and have the role of producing the extracellular matrix (ECM) which provides 
the arterial wall with high capability to withstand high pressure of circulating 
blood (Clark and Pyne-Geithman, 2005). Structurally, the cell membrane of 
VSMC contains caveolae (small invaginations) which increase the cell surface 
area significantly and within the cell, contractile proteins such as actin and 
myosin filaments are connected by dense bands and dense bodies (Figure 2.3). 
 
Figure 2.3 Structure of a vascular smooth muscle cell.  
 
Dense 
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Actin and myosin 
Mitochondrion 
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Function 
Smooth muscles can be categorised according to their function: (i) tonic or (ii) 
phasic contracting smooth muscle (Fisher, 2010). VSM displays characteristics 
of tonic smooth muscle and they are generally thought to be continuously 
contracted. Conversely, visceral smooth muscles, such as those found in the 
urogenital and gastrointestinal system, are phasic smooth muscle which 
displays rhythmic contractile activity (Fisher, 2010).  
VSM constitutes most of the intermediate layer (tunica media) of the blood 
vessels and their contraction and relaxation play an important role in the 
maintenance of blood pressure and the regulation of vascular resistance which 
are crucial in ensuring adequate blood flow to the surrounding tissues (Creager 
et al., 2006). Abnormal VSM contractions are associated with complications 
such as ischaemia, infarction and hypertension. In addition, VSM plays a role in 
blood vessel remodeling in physiological conditions e.g. exercise and 
pregnancy or after blood vessel injury (Owens et al., 2004). Under these 
circumstances, VSM increase their proliferation and migration and produce 
large quantities of extracellular matrix components. Hence, VSM is not only 
involved in short term regulation of vascular tone but are also involved in long 
term adaptation via structural remodeling of the vasculature. 
Regulation of vascular smooth muscle function 
VSM contraction and relaxation occurs as a direct result of the phosphorylation 
and dephosphorylation respectively of the myosin light chain (MLC). VSM 
contraction is initiated by an increase in intracellular Ca2+ ([Ca2+]i) due to an 
influx of Ca2+ from the extracellular space into the VSMC through voltage-gated 
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Ca2+ channels in the plasma membrane and the release of Ca2+ into the cytosol 
from the smooth sarcoplasmic reticulum intracellular stores down the 
concentration gradient.  Ca2+ binds to CAM to form the Ca2+-CAM complex 
which then activates myosin light chain kinase (MLCK) and causes 
phosphorylation of MLC, interaction between actin and myosin and 
subsequently VSM contraction (Figure 2.4) (Walsh, 1994). VSM relaxation, on 
the other hand, is initiated by a decrease in intracellular Ca2+ ([Ca2+]i) due to 
efflux of Ca2+ via the plasma membrane Ca2+ pump and Na+-Ca2+ exchanger 
and the reuptake of Ca2+ by the smooth sarcoplasmic reticulum Ca2+ pump. The 
fall in [Ca2+]i leads to Ca2+-CAM complex dissociation and followed by the 
dephosphorylation of the phosphorylated MLC by MLC phosphatase (Walsh, 
1994). 
 
 
 
- 
 
 
 
 
 
 
 
 
 
Ca2+ 
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Ca2+ + Calmodulin 
Ca2+ -Calmodulin 
MLCK 
+ 
- 
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Figure 2.4 Mechanism behind vascular smooth muscle contraction. 
Phosphorylated MLC leads to cross-bridge formation between actin filaments 
and myosin heads lead to VSMC contraction. 
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2.2 Cardiovascular Disease and Vascular Dysfunction 
 
2.2.1 Epidemiology of cardiovascular disease 
According to the World Health Organisation (WHO), CVD is the leading cause 
of global death and disability, accountable for one-third (17.3 million) of all 
annual deaths (WHO, 2012). WHO projected that by 2030, CVD will remain as 
the main cause of global mortality affecting 23.6 million people (WHO, 2012). In 
the United Kingdom in 2008, similar trends were observed with CVD being the 
leading cause of mortality, responsible for around one-third of all deaths 
(191000) annually (BHF, 2012). In UK in 2009, it was estimated that CVD costs 
the healthcare system approximately £8.6 billion annually (BHF, 2012). In 
addition, non-health care costs such as production losses due to CVD death 
and illness in the current workforce, cost the UK over £3 billion per annum 
(BHF, 2012). In view of the huge economic burden of treating already 
established CVD, it would be of wise to implement the more cost-effective 
cardiovascular prevention strategies. 
2.2.2 Risk factors of cardiovascular disease and cardiovascular risk 
score 
Throughout the years, the Framingham Heart Study which started in 1948 has 
identified numerous risk factors associated with CVD. These risk factors include 
age, sex, cigarette smoking, systolic blood pressure, diabetes mellitus, 
electrocardiogram-based left ventricular hypertrophy, total cholesterol and HDL 
cholesterol. Based on these risk factors, researchers have constructed risk 
scoring systems such as the well-established Framingham Cardiovascular Risk 
Score (FCVRS) and more recently in the UK, the QRISK®2 CV Risk Score 
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(Table 2.1 and Table 2.2). In Scotland, the Scottish Heart Health Extended 
Cohort develop a new CV risk score, ASSIGN to minimise the potential 
unfairness in the FCVRS when applied across different social groups in the 
same population. These efforts are important as it enables clinicians to identify 
and predict the CV risk of individual within a specified period hence allowing 
effective primary prevention against CVD. Current guidelines in the UK 
recommend that all adult aged 40 or more, and adults at any age who have a 
first-degree relative with hereditary lipid disorders and premature CVD to 
undergo at least every five yearly CV risk assessment (NICE, 2007). This 
means that adults younger than 40 years and/or those without CV risk factors or 
family history may be perceived as “healthy” and are misleadingly regarded as 
having no CVD risk when they may actually do. Moreover, it is uncertain 
whether these scoring systems are equally accurate at predicting CV risk 
across certain subgroups. It is recognised that the FCVRS have a tendency to 
overestimate risk in low and medium risk groups and underestimate risk for 
certain subgroups such as British Asians and people of African origin, people 
with Type I diabetes mellitus or Type 2 diabetes with nephropathy, people with 
hereditary lipid disorders, those with a strong family history of premature CVD 
etc (Brindle et al., 2006). The FCVRS also underestimated the true level of CVD 
in men with lower socioeconomic status (Woodward et al., 2007). Conversely, 
although FCVRS is widely used in the general population to stratify CV risk, the 
value of this risk score is less clear in younger adults and women. 
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Table 2.2 Predictors for Framingham Cardiovascular Risk Score (FCVRS). 
FCVRS predicts the chance of a person having CVD in the next 10 years and 
only applicable to adults aged 20 and older who do not have CVD, intermittent 
claudication and diabetes mellitus 
Age (years) 
Total cholesterol (mg/dL)  
HDL cholesterol (mg/dL) 
Smoking status 
Systolic blood pressure (mmHg) 
Treatment for hypertension 
Table 2.3 Predictors in the QRISK®2 CV Risk Score. Validation studies have 
concluded that QRISK®2 CV Risk Score is better calibrated to the UK 
population as it provides better risk estimates than Framingham risk score in 
identifying patients with high CVD risk in the UK (Hippisley-Cox et al., 2008) 
Age 
Sex 
Ratio of serum cholesterol to HDL 
levels 
Systolic blood pressure 
Body mass index 
Family history of premature CVD 
Smoking status 
Townsend deprivation score 
Treatment for hypertension 
 
2.2.3 Risk stratification of cardiovascular disease with vascular function 
tests 
It is not uncommon for patients to present with sudden unexpected death as the 
first manifestation of CVD (Priori et al., 2001). Annually, it is estimated that 1 in 
1000 in the general population dies of sudden cardiac death (Straus et al., 
2004). Since the mortality rates from out-of hospital cardiac arrests are 
distressingly high, it is therefore fundamental to identify alternate approaches to 
estimate CV risks especially in asymptomatic patients (Roger et al., 2011). 
Over the past few decades, vascular endothelial function has been extensively 
researched and this is reflected from the numerous publications over the years 
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which showed the effectiveness and accuracy of vascular function as a 
surrogate marker of CV health. Fichtlscherer et al. demonstrated that systemic 
vascular dysfunction predicts the recurrence of cardiovascular events in 
patients with acute coronary syndromes (Fichtlscherer et al., 2004). Gokce et al. 
found that impaired large vessel function is an independent predictor of long-
term CV events in patients with peripheral arterial disease whereas Shimbo et 
al. noted the same observation in a multi-ethnic population who previously had 
no history of cardiovascular diseases (Gokce et al., 2003, Shimbo et al., 2007). 
Furthermore, much research work carried out in the past has shown that most if 
not all, cardiovascular risk factors are associated with vascular dysfunction 
(Schächinger et al., 2000, Suwaidi et al., 2000, Halcox et al., 2002).  
2.2.4  Vascular dysfunction 
It is understood that the healthy human vasculature is pro-vasodilatator, anti-
inflammatory and exerts antithrombotic and antiplatelet properties which are 
central to prevent thrombotic events (Davignon and Ganz, 2004, Flammer and 
Lüscher, 2010). The endothelium- derived vasodilatator effect is known to be 
primarily mediated by the major vasodilator agent, NO. In endothelial 
dysfunction, there exists a disruption in balance between vasodilatator and 
vasoconstrictor agents resulting in an endothelium which promotes 
vasoconstriction, thrombosis, impairment of coagulation, platelet activation and 
leukocyte adherence as well as VSMC proliferation and migration (Verma and 
Anderson, 2002) (Figure 2.5). Under these circumstances, endothelium-
dependent vasoconstriction predominates due to the release of vasoconstrictor 
agents such as endothelin-1 and angiotensin II. In addition, the concomitant 
lack of NO bioavailability results in a reduction of blood vessel vasodilatation 
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and a disruption in the vascular growth remodeling mechanism favouring all 
stages of atherogenesis. The lack of NO bioavailabilty could be explained by 
the following: (i) a reduction in eNOS expression; (ii) inadequate substrate L-
arginine or co-factors for eNOS or the presence of antagonists such as 
asymmetric dimethyl arginine; (iii) impaired activation of eNOS and (iv) an 
increased NO degradation (Faulx et al., 2003).  
 
 
 
 
 
Figure 2.5 Phenotypic characteristics of healthy and diseased endothelium 
It is known that endothelial lining injury coupled with endothelial dysfunction 
appears to be an early pivotal event in atherogenesis and has been 
demonstrated to herald the development of clinically detectable atherosclerotic 
plaques in the coronary arteries (Mano et al., 1996, Ross, 1999, Glass and 
Witztum, 2001). Considering the fact that controlling and treating cardiovascular 
risk factors such as hypercholesterolaemia, hypertension, hyperglycaemia and 
stopping smoking, leads to the reversal of endothelial dysfunction, endothelial 
dysfunction can therefore be used as a surrogate marker for predicting the risk 
of developing  CVDs in addition to being a primary therapeutic target in 
preventing atherosclerotic disease. 
Healthy endothelium 
Vasodilatation 
Anti-thrombotic 
Anti-inflammatory 
Anti-oxidant 
Anti-VSMC proliferation and 
migration 
Endothelial dysfunction 
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Pro-thrombotic 
Pro-inflammatory 
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Pro-VSMC proliferation and 
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2.2.5 Pathophysiology of vascular dysfunction 
Under homeostatic conditions, the maintenance of vascular tone and blood 
fluidity is tightly regulated by the endothelium. In addition, proinflammatory 
factors such as tumour necrosis factor-α (TNFα) and C-reactive protein (CRP) 
are not or minimally expressed in the vasculature. However, when both 
traditional and novel cardiovascular risk factors such as hypercholesterolaemia, 
hypertension, hyperglycaemia, smoking, advancing age, and a family history of 
premature atherosclerotic disease are present, a chronic inflammatory process 
is initiated which results in alteration in endothelial function. This alteration can 
be seen as reduction in antithrombotic factors and an increase in 
vasoconstrictor and prothrombotic products (Widlansky et al., 2003). It is also 
now recognised that risk factors including obesity, raised C-reactive protein and 
chronic systemic infection are related with endothelial dysfunction (Widlansky et 
al., 2003). 
Since it is clear that peripheral vascular function is predictive of CV function, 
surrogate markers of vascular function in the peripheries could potentially be 
indicators of CV risk. One of these potential surrogate markers could be 
potassium channels which can be found in VSMCs.  
The next chapter will discuss about the role of KATP channels in peripheral 
vasoregulation and how these channels can potentially be surrogate markers of 
vascular function. 
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CHAPTER 3  
ATP-sensitive potassium channels (KATP 
channels) 
3.1 Background  
The importance of potassium channels and their role in vivo are gaining 
recognition among researchers. Amidst the different potassium channels 
expressed in vivo, the least understood are the KATP channels in endothelium 
and VSMCs (Köhler and Ruth, 2010). Not much is known about these channels, 
however, some effort has been made in the past, using genetically manipulated 
mice models to allow a greater understanding of the physiological and 
pathophysiological roles of these KATP channels (Seino and Miki, 2003). 
The endothelium and vascular smooth muscle cells express four different 
classes of potassium ion channels: (1) voltage-gated potassium channels (KV); 
(2) Ca2+-activated potassium channels (KCa); (3) ATP-sensitive potassium 
channels (KATP) and (4) inwardly rectifying potassium channels (Kir) (Hibino et 
al., 2010). Of particular interest to this study are the KATP channels in 
endothelium and vascular smooth muscle cells since they have been shown to 
be downregulated in disease states such as diabetes (Mayhan, 1994, 
Zimmermann et al., 1997, Miura et al., 2003) and hypertension (Sobey, 2001) 
where vascular dysfunction is the hallmark of these diseases (Puddu et al., 
2000, Calles-Escandon and Cipolla, 2001). It would be of interest to examine 
the feasibility of assigning a quantitative measure to vascular dysfunction by 
assessing the levels of KATP channels. 
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 3.2 General features of KATP channels 
KATP channels are potassium-ATP-sensitive pores. They were first identified in 
heart muscles and since then were found to be expressed in a variety of tissues 
such as the pancreatic β-cells, skeletal muscle, the brain, vascular smooth 
muscle and endothelium (Noma, 1983). In the heart, activation of KATP channels 
was shown to play a cardioprotective role against cardiac failure (Yamada et al., 
2006). In the pancreatic β-cells, they regulate glucose-stimulated insulin 
secretion whereas in skeletal muscles, they are key in controlling insulin-
dependent glucose uptake into these muscles (Aguilar-Bryan et al., 2001, Lin et 
al., 2005, Ashcroft and Gribble, 1999, Seino et al., 2008). On the other hand, 
KATP channels activation in the brain has a neuroprotective effect against 
metabolic challenge (Zeng et al., 2007). In the endothelium and VSMCs, KATP 
channels have been reported to play an important role in regulating vascular 
tone (Standen et al., 1989). 
The KATP channels provide a link between the cellular metabolism and 
membrane electrical excitability. One of the characteristics of these channels is 
that their open-state probability depends on the concentrations of intracellular 
ATP, ADP and other nucleotides. In other words, these channels are regulated 
by intracellular ATP and ADP. Furthermore, they are targets which can be 
activated pharmacologically by chemicals such as K+ channel openers e.g. 
iptakalim and be inhibited by sulphonylurea derivatives e.g. glibenclamide. It is 
not exactly clear what role KATP channels play in vascular dysfunction but it was 
widely agreed that they are responsible for the maintenance of the resting 
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potential of endothelial cells and the regulation of release of vasoactive 
compounds (Wang et al., 2007).  
KATP channels are targets of endogenous vasodilators, primarily NO, and 
vasoconstrictors, such as endothelin-1 (Quayle et al., 1997). Previous studies 
have shown that activation of KATP channels using K+ channel openers such as 
nicorandil results in membrane hyperpolarisation, a reduction in voltage-
dependent Ca2+ channel activity and ultimately vasodilatation of VSMCs 
(Jackson, 1998, Brayden, 2002). On the other hand, blocking KATP channels, 
both in vitro and in vivo, leads to membrane depolarisation and vasoconstriction 
of VSMCs (Kubo et al., 1997).  In disease states such as hypertension and 
diabetes, the activity of the KATP channels appear to be downregulated 
(Zimmermann et al., 1997, Miura et al., 2003). In animal models, disruption of 
KATP channels in VSMCs results in coronary arteries vasospasm and sudden 
cardiac death (Miki et al., 2002, Chutkow et al., 2002). These observations not 
only demonstrate the importance of KATP channels in regulating vascular tone in 
animal models but also raises some important questions- could these channels 
possess similar function in humans? If this is the case, could KATP channels 
potentially act as blood biomarker of vascular dysfunction in humans? This 
research project will attempt to address these questions. 
Structurally, KATP channels are octamers (Clement et al., 1997, Shyng and 
Nichols, 1997) which consist of: 4 α-subunits [the pore-forming inwardly 
rectifying potassium channels (Kir6)] and 4 β-subunits [the ATP-binding 
sulphonylurea receptors (SUR)]. To date, two Kir6.x genes (KCNJ8 for Kir6.1 
and KCNJ11 for Kir6.2) and two SUR genes (ABCC8 for SUR1 and ABCC9 for 
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SUR2A and Sur2B) are identified (Inagaki et al., 1995, Inagaki et al., 1996, 
Standen, 2003, Shi et al., 2012). Both Kir6 and SUR components are required 
to form a complete active KATP channel giving a 1:1 stoichiometry (Aguilar-Bryan 
et al., 1998). In the vascular smooth muscle, the molecular identities of these 
KATP channel isoforms have not been determined to the same degree of 
certainty as the other KATP channels such as those found in the pancreatic β-cell 
(Kir6.2/SUR1) and cardiac muscle (Kir6.2/SUR2A) (Standen, 2003, Teramoto, 
2006). Two types of channels namely Kir6.2/SUR2B channels (Isomoto et al., 
1996) and Kir6.1/SUR2B channels (Yamada et al., 1997) have been cloned and 
identified in the VSMCs. Nonetheless, there is good evidence that 
Kir6.1/SUR2B channel plays a more important role in vascular smooth muscle 
(Figure 3.1) (Suzuki et al., 2001).  
 
 
 
 
 
 
 
Figure 3.1 The structure of the vascular smooth muscle KATP channels. Kir6.1 
is the pore-forming subunit whereas SUR2B is the regulatory subunit. 
 
Kir6.1 SUR2B 
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3.3 Evidence that KATP channels exist in the human 
blood cell 
 
It was thought by Du and Jovanovic (unpublished results) and several other 
researchers that both Kir6.1/SUR2B subunits of KATP channels would be 
present in human blood cells as well, since they are expressed in mice blood 
cells (specifically leukocytes) (Du and Jovanovic, unpublished results, Da Silva-
Santos et al., 2002, Pompermayer et al., 2005, Zanardo et al., 2006). Da Silva-
Santos et al. (2002) established that inflammatory neutrophil migration was 
mediated by KATP channels in mice. They showed that glibenclamide, a KATP 
channel blocker, decreases the exudation and neutrophil influx whereas 
minoxidil, a KATP channel opener, increases the exudation and neutrophil influx 
(Da Silva-Santos et al., 2002). Zanardo et al. (2006) demonstrated that 
hydrogen sulphide, an endogenous vasodilator, down-regulated leukocyte 
adherence via the activation of KATP channels which were found on the 
leukocytes of rats themselves (Zanardo et al., 2006). This is strongly supported 
by more recent studies by Dal-Secco et. al. (2008) and Spiller et. al. (2010) 
(Dal-Secco et al., 2008, Spiller et al., 2010). Both respectively showed that 
neutrophil migration during an inflammatory and infection response rely on a 
KATP-dependent mechanism. 
3.4 Understanding of the pathophysiological roles of 
KATP channels from genetically manipulated mice 
models  
 
Genetic manipulation of the KATP channels mRNA subunits in animal models 
such as mice have clarified some of the many pathophysiological roles of KATP 
channels in the vasculature. Two studies of animal models, Kir6.1 knockout 
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mice and SUR knockout mice, have demonstrated that both knockout mouse 
models do not exhibit KATP channel activity in the smooth muscle cells of the 
aorta and that there was no pinacidil-induced vasodilation observed (Miki et al., 
2002, Chutkow et al., 2002). These findings suggest that both Kir6.1 and SUR2 
mRNA subunits are required to form a fully functioning KATP channel and that 
the activation of Kir6.1/SUR2 channels has an important role in mediating the 
vasodilator effects of potassium channel openers in VSMCs (Seino and Miki, 
2003). 
3.5 Role of KATP in vascular dysfunction 
Various studies have been conducted and showed that activation of KATP 
channels in the vasculature results in the protection against vascular 
dysfunction. One such study found that iptakalim, a new KATP channel opener, 
protects endothelial cells against vascular dysfunction through the activation of 
KATP channels which inhibits the release and synthesis of endothelin-1 and 
increases NO release and endothelial NO synthase activities (Wang et al., 
2007). This finding was supported by Long et. al. (2008) and Pan et. al. (2010) 
where they reported that the activation of KATP channels by iptakalim protected 
vascular function against hypertension (Pan et al., 2010) and renal injury (Long 
et al., 2008).  On the other hand, Date et. al. (2005) showed that nicorandil, also 
a KATP channel opener, is capable of preserving vascular function by inhibiting 
endothelial cell apoptosis through mitochondrial KATP channels (Date et al., 
2005).  
The exact mechanism as to how KATP channel activation leads to the protection 
against vascular dysfunction is unclear. However, three possible pathways have 
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been implicated. They are: (i) NO/cGMP pathway, (ii) prostaglandin/cAMP 
pathway and (iii) adenosine/cAMP/protein kinase A (Nelson and Quayle, 1995, 
Kleppisch and Nelson, 1995, Quayle et al., 1997, Standen and Quayle, 1998). 
There is accumulating evidence that KATP channels expressed in different 
tissues can be modulated by NO. In the heart, Shinbo and Iijima showed that 
NO potentiates the action of K+ channel openers on the KATP channels via an 
unknown mechanism (Shinbo and Iijima, 1997). This finding was validated by 
subsequent studies and it was suggested that the possible mechanism by which 
NO exerts its effect on KATP channels is through the NO/cGMP/PKG pathway 
(Baker et al., 2001, Han et al., 2002, Cuong et al., 2006). In pancreatic β-cells, 
KATP channels activation by NO is likely due to decreased production of ATP as 
a result of impaired glucose metabolism (Tsuura et al., 1994), while in VSMCs, 
activation of KATP channels by NO was suggested via a cGMP-mediated 
pathway leading to blood vessel vasodilatation (Kubo et al., 1994, Murphy and 
Brayden, 1995).  
Only one study to date was carried out to determine the relationship between 
levels of KATP channels in blood cells and vascular function in humans (Choong, 
2010 (unpublished results)). In the current project the aim is to investigate this 
relationship and examine the feasibility of using KATP channels levels in blood 
cells as a possible biomarker of vascular dysfunction. 
In the following chapter, the different modalities available to assess vascular 
function invasively and non-invasively will be described and discussed. 
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CHAPTER 4 
Assessment of vascular function in humans  
4.1 Background 
The assessment of vascular function includes the measurement of endothelial 
function and arterial stiffness.  When assessing endothelial function, 
interventions such as administration of vasoactive agents like acetylcholine; or 
mechanical stimulus such as shear stress, are applied onto the vessel in 
question (Verma et al., 2003). In the healthy vascular endothelium, 
endothelium-dependent vasodilatation predominates primarily through the 
release of endothelial-derived NO. Conversely, in vascular endothelial 
dysfunction, an impaired endothelium-dependent vasodilation or paradoxical 
vasoconstriction can be observed. Vascular endothelial function can be 
assessed either invasively or non-invasively in the coronary or peripheral 
circulations (Hadi et al., 2005). Some techniques are summarised in Table 4.1. 
Doppler Echocardiography, PET and phase contrast MRI will not be discussed 
in this section as they are out with the scope of the study. The vasculature can 
also be subdivided into macrovessels or microvessels. The assessment of 
macrovessels or microvessels overlaps with the assessment of the coronary 
and peripheral circulations as stated in Table 4.1. Briefly, macrovessels are 
conduit arteries that play an important role in distributing blood flow from the 
heart to the different organs in the body. In addition, it helps to reduce the load 
on the heart and increase blood pressure during diastole by providing 
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compliance to each stroke volume produced by the heart. On the other hand, 
microvessels have the role of regulating local vascular resistance in response to 
local demand as well as to control blood flow to tissues and organs. Arterial 
stiffness measurement is another domain of vascular function assessment. This 
can be measured using the Pulse Wave Analysis test as illustrated below.  
Table 4.1 Methods for assessing vascular function.  
Central circulation Peripheral circulation 
Invasive Non-invasive Invasive Non-invasive 
Intracoronary 
agonist infusion 
with quantitative 
coronary 
angiography and 
intracoronary 
Doppler* 
Doppler 
Echocardiography* 
Intrabrachial 
infusion of 
agonist with 
Venous 
Occlusive 
Plethysmography 
(VOP)^ 
Carotid Intima-
Media Thickness 
(CIMT) on 
Ultrasound* 
 Positron Emission 
Tomography* 
 Brachial Artery 
Flow-mediated 
Dilatation (FMD)* 
 Phase contrast 
MRI* 
 EndoPAT^ 
   Pulse Wave 
Velocity (PWV)* 
   Pulse Wave 
Analysis (PWA)*^ 
   Iontophoresis with 
Laser Doppler 
Flowmetry (LDF)^ 
   Post-occlusive 
Reactive 
Hyperaemia with 
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Full-field Laser 
Perfuser Imager 
(FLPI)^ 
PWV and PWA measure arterial stiffness; the other tests measure vascular 
endothelial function. 
*Assessment of macrovessels 
^Assessment of microvessels 
 
4.1.1 Intracoronary agonist infusion with quantitative coronary 
angiography and intracoronary Doppler 
 
Intracoronary agonist infusion with quantitative coronary angiography is one of 
the earliest methods used to evaluate coronary endothelial function in response 
to intracoronary infusion of an agonist such as acetylcholine or increase in 
blood flow (Ludmer et al., 1986, Cox et al., 1989, Hadi et al., 2005). To measure 
coronary blood flow velocity in response to the agonist, a Doppler catheter is 
positioned into the studied epicardial coronary artery, such as the left anterior 
descending artery, using a guide catheter (Nabel et al., 1990). Coronary blood 
flow can be calculated from the velocity and the cross sectional area of the 
blood vessel which can be obtained by quantitative coronary angiography 
(Figure 4.1) (Newby, 2000). Infusion of the agonist into the coronary artery is 
through the Doppler catheter. Angiography is performed after the bolus injection 
within a specific time. This is followed by recovery and intracoronary infusion of 
nitroglycerin to test endothelium-independent vasodilatation. In healthy vascular 
endothelium, an increased in blood flow velocity as a result of endothelium-
dependent vasodilatation can be observed. In endothelial dysfunction, there is 
an abnormal vasomotor response whereby the vessel fails to dilate in response 
to the agonist. 
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Figure 4.1 Changes in coronary artery cross-sectional diameter obtained by 
quantitative coronary angiography (a) Baseline; (b) ACH infusion; (c) 
Nitroglycerin administration (Adapted from Richartz et al., 2001). 
 
4.1.2 Intrabrachial infusion of agonist with venous occlusive 
plethysmography 
 
This method involves the infusion of endothelium-dependent agonists such as 
acetylcholine into the brachial artery and the subsequent measurement of the 
vasomotor responses of forearm resistance vessels using venous occlusion 
plethysmography (VOP) (Widlansky et al., 2003b). Unlike the study of coronary 
circulation, this method allows the evaluation of vascular endothelial function in 
a more accessible vascular bed. Since vascular dysfunction is recognised as a 
diffuse pathology, peripheral vascular abnormalities have been shown to 
correlate significantly with coronary vascular abnormalities, therefore, allowing 
peripheral vascular testing to be an indirect surrogate of coronary vascular 
function (Kuvin et al., 2007).  
VOP is a widely used method for assessing forearm blood flow (Figure 4.2). It 
was first described by Hewlett and Zwaluwenburg in 1909 and has remained 
essentially the same since then (Hewlett and Zwaluwenburg, 1909). The 
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underlying principle involves occlusion of venous outflow from the forearm but 
not arterial inflow which results in swelling of the forearm due to an increase in 
forearm volume over time (Alam et al., 2005). The forearm blood volume can be 
measured by voltage-dependent strain-gauge and it is a direct indicator of 
forearm arterial blood inflow (Wilkinson and Webb, 2001). VOP allows forearm 
vascular resistance to be tested and by manipulating intrabrachial infusion of 
vasoactive agents, changes in forearm vascular resistance can be a good 
reflection of normal vascular endothelial function (Alam et al., 2005). Studies 
that have utilised VOP to assess vascular function include those that are carried 
out by Panza et. al. (1900) and Creager et. al.(1900) (Panza et al., 1990, 
Creager et al., 1990). Panza et. al. (1990) showed impaired endothelium-
mediated vasodilatation in response to acetylcholine in a group of patients with 
essential hypertension (Panza et al., 1990). Using intrabrachial artery infusions 
of methacholine and nitroprusside with VOP, Creager et. al. (1990) 
demonstrated, on both occasions, blunted vasodilator responses in humans 
with hypercholesterolaemia (Creager et al., 1990).  
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Figure 4.2 Assessment of forearm blood flow using venous occlusion 
plethysmography (Adapted from http://arwatch.co.uk/2011/11/allopurinol-to-
reduce-cad-mortality/ (2013)). 
 
4.1.3 Carotid intima-media thickness using ultrasound  
Carotid intima-media thickness (CIMT) is a method widely used as a proxy end 
point in observational studies and research trials to predict CVD risk (Bots et al., 
1997, Chambless et al., 1997, Hodis et al., 1998, O'Leary et al., 1999). The 
relationship between CIMT and CVD has been well established and CIMT has 
been shown to be an independent predictor of future CVD (Chambless et al., 
1996, O'Leary et al., 1996, Chambless et al., 1997, O'Leary et al., 1999, Lorenz 
et al., 2007). This method also provides a measure of sub-clinical 
atherosclerosis, its progression and the degree of success in therapeutic 
intervention for preventing atherosclerosis. In addition, it is approved by the US 
Food and Drug Administration (FDA) as a marker of subclinical atherosclerosis. 
In brief, CIMT involves the measurement of the thickness of the intimal and 
medial layers of the carotid artery using B-mode ultrasound (Hurst et al., 2007) 
(Figure 4.3). Based on the Manheim Intima-media Thickness Consensus Panel, 
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a plaque is defined as a focal structure that builds up in the inner surface of the 
arterial lumen of at least 0.5mm or 50% of the surrounding IMT value or 
demonstrates a thickness ˃ 1.5mm as measured from the tunica media-to-
tunica adventitia interface to the tunica intima lumen interface (Touboul et al., 
2007). Since CIMT is highly reproducible, simple, safe, noninvasive yet 
relatively inexpensive technique, it appears to be an attractive approach to the 
investigation of the cumulative effect of atherosclerosis risks.  
 
Figure 4.3 Image of the carotid artery obtained using ultrasound in carotid IMT 
(Adapted from Hurst et al., 2007). 
 
4.1.4 Brachial artery flow-mediated dilatation 
Flow-mediated dilatation (FMD) reflects endothelium-dependent vasodilatation 
of an artery in response to an increase in luminal blood flow (reactive 
hyperaemia) and internal-wall shear stress (Pyke and Tschakovsky, 2005, 
Thijssen et al., 2011). By measuring the luminal diameter of the artery before 
and after ischaemic cuff occlusion, vascular endothelial function can be 
estimated as FMD percentage change which represents the increase in artery 
diameter from resting conditions to maximum artery vasodilatation during 
reactive hyperaemia. FMD was first developed by Celermajer et. al. in 1992 and 
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since then, FMD has been extensively used as a non-invasive technique to 
measure macrovessel function in peripheral arteries such as the brachial artery, 
radial and femoral artery (Celermajer et al., 1992). The FMD of these peripheral 
arteries are often taken to represent the response of the central circulation 
(Anderson et al., 1995, Takase et al., 1998). In addition, FMD has been shown 
to be a reliable indicator of vascular function (Schroeder et al., 1999, Herrington 
et al., 2001, Meirelles et al., 2007, Simova et al., 2008, Pala et al., 2009). 
However, it is recognised that the reliability of FMD is dependent on various 
factors such as cuff placement site, duration of occlusion, addition of ischaemic 
handgrip exercise and the experience of the sonographer (Pyke and 
Tschakovsky, 2005). Furthermore, the coefficients of variation for brachial artery 
FMD have been reported to vary from as little as 1.5% to 50% in others 
(Sorensen et al., 1995, Andrews Md et al., 1997, de Roos et al., 2001). 
However, it is largely agreed that a normal brachial artery vasodilates about 5 to 
15% from resting diameter post cuff release (Berry et al., 2000, Vogel, 2001). 
To address the disparities in FMD techniques across different research centres, 
guidelines for FMD procedures have been published to support standardisation 
of FMD measurements (Mullen et al., 2001, Coretti et al., 2002). Since FMD is 
non-invasive, well-tolerated, it can be safely used as a tool of measuring 
macrovessel endothelial function in studies involving large patient populations 
over-time. However due to technical difficulties, dependence on costly 
equipment and large interindividual differences, FMD has not been utilised in 
daily clinical practice.  
The underlying physiological mechanism of FMD has been extensively 
investigated but it is not well understood. It is proposed that the mechanisms 
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mainly responsible for the observed FMD response may change over time when 
there is a prolonged shear stress stimulus (Pyke and Tschakovsky, 2005). 
Mullen et. al. (2001) suggested the possibility of sequential recruitment 
mechanisms i.e. prolonged shear stress will eventually lead to another 
mechanism taking over as the one that is primarily responsible for the FMD 
response (Mullen et al., 2001). However, it is generally agreed that the 
immediate FMD response is mainly mediated by NO (Pyke and Tschakovsky, 
2005). During FMD, high resolution Doppler ultrasonography is used to scan the 
conduit artery e.g. the brachial artery under resting condition and post cuff 
release (reactive hyperaemia phase) which are induced by the inflation and 
deflation of the blood pressure cuff. The cuff is normally placed around the 
forearm distal to the site of ultrasound scan of the artery. The resultant shear 
stress caused by an increased in blood flow following ischaemic cuff released 
induces endothelium-dependent NO release, which in turn results in 
vasodilatation of the artery. Hence, based on previous studies, brachial artery 
FMD reflects NO bioavailability and its impairment signify conduit artery 
dysfunction which has been shown to correlate with the presence and severity 
of coronary artery disease (Nabel et al., 1990, Anderson et al., 1995, Neunteufl 
et al., 1997, Kaku et al., 1998, Neunteufl et al., 2000). In addition, brachial 
artery FMD was reported to predict restenosis in patients undergoing 
percutaneous coronary revascularisation (Patti et al., 2005) and ischaemic 
episodes in patients with ischaemic heart disease and hypercholesterolaemia 
(Søndergaard et al., 2002). Several studies have also found that FMD was 
predictive of CV events in high CV risk subjects (Gokce et al., 2002, Gokce et 
al., 2003, Akcakoyun et al., 2008). Gokce et. al. (2002). Nonetheless, FMD 
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responses should be interpreted with care as most recent FMD study by Wray 
et al. (2013) suggests that these responses should be viewed as endothelium-
dependent vasodilatation but not necessarily NO-dependent vasodilation (Wray 
et al., 2013). 
4.1.5 Endo-peripheral arterial tone  
A more convenient way of assessing endothelial function is by using peripheral 
arterial tonometry (EndoPAT). The EndoPAT device consists of a fingertip 
plethysmograph which has the ability to detect volume changes in the fingertips 
with every arterial pulsation (Figure 4.4) (Axtell et al., 2010). This test involves 
placing finger probes on the index fingers of both hands and measuring digital 
pulse amplitude in the fingertip on one hand both at rest and after inducing 
reactive hyperaemia. Reactive hyperaemia is induced by inflating the blood 
pressure cuff to suprasystolic pressure and then rapidly deflating the cuff on the 
arm, temporarily decreasing blood flow to the fingers. The changes in digital 
pulse amplitude in response to reactive hyperaemia are expressed as reactive 
hyperaemia index (RHI). It is calculated as the ratio of the average pulse wave 
amplitude of the PAT signal over one minute, starting one minute after cuff 
release,  divided by the average pulse wave amplitude at baseline i.e. 3.5-min 
time period before cuff inflation (Syvänen et al., 2011). This measurement 
reflects the local peripheral arterial tone. Measurements are also taken 
simultaneously in the contralateral arm to act as control for vascular tone 
changes which are independent of the endothelium (Figure 4.4). The precise 
technique involved in performing the EndoPAT test can be found in the paper 
published by Axtell et al (2010) (Axtell et al., 2010).  
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It has been shown that PAT correlated with traditional CV risk factor such as 
higher cholesterol, body mass index, smoking and diabetes and has been 
validated for the detection of impaired coronary microvascular function (Bonetti 
et al., 2004). The RHI score is also recognised to exhibit an excellent 
association with measures of coronary and peripheral vascular dysfunction 
(Kuvin et al., 2007). 
The EndoPAT is a relatively rapid (15-30 minutes) and operator-independent 
method of assessing the effects of CV risk factors on endothelial function. Table 
4.2 summarises the advantage and disadvantages of this technique. In addition, 
EndoPAT is a validated method that can be used to determine the effects of 
therapeutic interventions and lifestyle changes on vascular function (Moerland 
et al., 2011)  
  
Figure 4.4 On the top left corner- the PAT device, which is a plastic cap with a 
closed end, is placed on an index finger of each hand. Tubes running from the 
finger probes connect the EndoPAT device to a recording unit that conveys data 
directly to a computer for analysis. On the right- a diagrammatic illustration of 
the device showing a longitudinal section of the finger probes. The device 
contains air-filled chambers with sensors which detect changes in finger volume 
with each arterial pulsation. On the bottom left corner- the normal setup for a 
research study is demonstrated (Adapted from Axtell et al., 2010). 
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Table 4.2 Advantages and disadvantages of EndoPAT. 
Advantages 
 Easy to perform 
 Non-invasive 
 Non operator-dependent with 
comprehensive automatic 
analysis 
Disadvantages 
 Expensive 
 Difficult to interpret as increased 
vasoreactivity in vasculature in  
the finger  
 
4.1.6 Pulse Wave Velocity 
Pulse wave velocity (PWV) is a direct marker of arterial stiffness that can be 
measured noninvasively. It is now well recognised that PWV is an independent 
predictor of cardiovascular mortality and morbidity (Benetos et al., 2002, 
Abraham et al., 2010). The standard method of measuring PWV is to record 
pressure waves between arterial segments at two different sites on the arterial 
tree. Measurement of PWV between the common carotid and femoral artery is 
the gold standard technique due to its reproducibility, accuracy, relatively easy 
to measure and low costs (Laurent et al., 2006, Joly et al., 2009). However, 
more importantly, much research has shown that the carotid-femoral PWV is 
correlated with the incident of CVD, independent of traditional CV risk factors 
and in different populations (Blacher et al., 1999, Laurent et al., 2001, 
Cruickshank et al., 2002, Shokawa et al., 2005, Sutton-Tyrrell et al., 2005, 
Mattace-Raso et al., 2006, Choi et al., 2007).  
There are several different methods of measuring PWV noninvasively (Joly et 
al., 2009): 
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(i)      Simultaneous measurements (Complior device)- measures the pulse 
transit time between the common carotid and femoral artery using 
mechanotransducers (Figure 4.5) and simultaneously records the 
pressure pulses in the form of pressure waves. The 
mechanotransducers are applied directly onto the skin with the first 
probe positioned at the base of the neck on the common carotid 
artery (the central detection site) and the second probe placed over 
the femoral artery. The pulse transit time is measured from the 
beginning of each waveform where the steep rise starts. PWV can be 
derived with the following formula: 
 where  is the distance traveled and  is the time 
for the wave to travel that distance 
  
(i)       Sequential or non-simultaneous measurements- applanation 
tonometry (SphymoCor, AtCor Medical) is another method used to 
measure carotid-femoral PWV (Figure 4.6). This technique involves 
sequential or non-simultaneous detection and recording of carotid 
and femoral pressure waveforms using sensitive tonometers. 
Tonometers are instruments used to measure pressure and tension 
(Salvi et al., 2008). At both sites, an ECG trace is also recorded. PWV 
is calculated according to the formula above with the distance divided 
by the time delay measured between pressure upstroke at carotid 
and femoral artery site (Joly et al., 2009).  
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Figure 4.5 Pulse transit time are measured between two arterial sites i.e. the 
carotid and the femoral artery (Adapted from 
http://www.freepatentsonline.com/6511436.html (25-10-2013)).  
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Figure 4.6 Sequential measurements of carotid-femoral PWV.  
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4.1.7 Pulse Wave Analysis 
Pulse wave analysis (PWA) is a technique which is used to assess arterial 
stiffness indirectly. Using applanation tonometry, PWA allows accurate 
recording of radial (peripheral) pressure waveforms and subsequent generation 
of the corresponding aortic (central) waveform using a generalised transfer 
function (Figure 4.7) (O'Rourke et al., 2001). This allows the derivation of the 
augmentation index (AIx) (an index of arterial stiffness) and central pulse 
pressure. Higher values of AIx suggest increased PWV (due to increased 
arterial stiffness) and vice versa. The PWA technique is described in more detail 
in Chapter 4.  
 
 
 
 
 
 
Figure 4.7 On the left - the peripheral or radial pulse waveform obtained 
through applanation tonometry. One the right- central or aortic pulse waveform 
derived from the peripheral waveform after the application of a generalised 
transfer function. 
 
Several studies have reported associations between AIx and certain clinical 
conditions such as advanced age, hypertension, chronic kidney disease and 
CVDs such as myocardial infarction and coronary artery disease (Kelly et al., 
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1989, Mitchell et al., 1997, Chae Cu, 1999, London et al., 2001, Safar et al., 
2002, Williams et al., 2006). AIx may therefore be a useful therapeutic tool to 
monitor disease changes in selected patient populations. It has been shown 
that in hypertensive patients, AIx change in response to antihypertensive 
therapy was superior to conventional cuff measurement in predicting left 
ventricular mass change (Hashimoto et al., 2007). In addition, the Sixth 
International Workshop on Structure and Function of the Vascular System 
produced a consensus document which supports the notion  that central 
haemodynamics measured by applanation tonometry has a robust predictive 
value for CV events (Agabiti-Rosei et al., 2007). This mounting evidence 
suggest that the central pressure and indices obtained from PWA could prove to 
be relatively straightforward, noninvasive and useful tool to predict CV risk in 
patients in the clinical setting. 
4.1.8 Laser Doppler flowmetry with iontophoresis 
This is a noninvasive method commonly used to study the dynamics of skin 
microcirculation providing insight to endothelial function. This technique allows 
the delivery of vasoactive substances, such as acetylcholine and sodium 
nitroprusside, to the skin and provides a continuous, sensitive and real time 
assessment of cutaneous blood flow.  
Laser Doppler flowmetry 
LDF is based on the principle of Doppler effect whereby the emitted laser light 
travels through skin and interacts with both static tissue and moving objects 
such as red blood cells. The Doppler effect is the relative frequency change 
between the moving source and the static detector. The wavelength of the light 
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that is backscattered from stationary tissue remains the same frequency 
whereas the wavelength of the light that is reflected from moving red blood cells 
differs slightly depending on the speed of the moving red blood cells. When this 
difference is detected and analysed, information about the density of the moving 
red blood cell and flux can be obtained.  Flux, F, is the product of RBC density 
(N, the number of RBC in the sample) and their velocity,s (Murray et al., 2004).  
F=ksN where k is an arbitrary constant. 
Since it is recognised that there is a linear correlation between the RBC flux and 
skin blood flow, the RBC flux is taken as an approximation of blood flow. This is 
the reason why flux signals are not absolute values and are usually expressed 
in arbitrary perfusion units (P.U.)  
The Doppler effect was first utilised by Stern to monitor blood flow (Stern, 
1975). Using a helium-neon laser, he demonstrated the difference in fingertip 
blood perfusion under normal blood flow conditions and under brachial artery 
occlusion. Since then, the method of LDF has undergone continuous 
improvement over the last 30 years. The LDF, which is a non-invasive 
technique, is a single-point perfusion monitoring system (Figure 4.8(a)) widely 
used both in research and as a diagnostic tool in the clinical setting to aid 
measurement of blood flow in the microcirculation. However, since skin 
circulation is known to be heterogeneous, laser Doppler imaging (LDI) (Figure 
4.8(b)) was developed to allow blood flow data to be collected over a larger skin 
area. The fundamental principle underlying LDF and LDI is demonstrated in 
Figure 4.8. 
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Figure 4.8(a) Schematic diagram representing LDF which is a single-point 
probe consisting of an emitting delivery fiber with the source of laser light and a 
separate collection fiber that serve as receivers; (b) Schematic diagram 
representing LDI (Adapted from Murray et al., 2004). 
 
The depth of penetration of the emitted laser light varies among tissue: for skin, 
it is approximately 0.5-1mm. In view of the anatomical organisation of skin 
microcirculation, the LDF is an ideal method for capturing blood flow signals 
from the superficial nutritional to deeper thermoregulatory blood vessel. 
In research, it has been shown that patients with increased risk for CVD are 
characterised by impaired cutaneous ACH-induced vasodilatation (Ijzerman et 
al., 2003).  In addition, Khan et. al. (2008) demonstrated that cutaneous 
vasodilatation to ACH correlates with coronary microvascular function (Khan et 
al., 2008). Since it is understood that coronary microvascular dysfunction is part 
of a systemic microvascular process, iontophoresis with LDF serves to be an 
attractive method to stratify cardiovascular risk (Brocx and Drummond, 2009, 
Turner et al., 2008, Ijzerman et al., 2003).  
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Iontophoresis 
The term iontophoresis refers to the delivery of charged pharmacological 
substances through biological membrane using an externally applied low-
density electric current (Holowatz et al., 2008, Turner et al., 2008, Roustit and 
Cracowski, 2012). This technique was first popularised by Leduc, one of the 
scientists who pioneered this technique at the beginning of the 20th century as a 
result of his animal research work (Chien and Banga, 1989, Rawat et al., 2008).   
Iontophoresis is a technique based upon the general principle that similar 
charges repel each other while opposite charges attract each other. An electric 
current is applied externally to increase the penetration rate of the 
pharmacological substances through the biological membrane such as the skin. 
When a positively charged substance is to be delivered transdermally, it is 
placed in the surrounding of the positively charged electrode (anode) from 
which it is repelled (Figure 4.9). The positively charged substance is 
subsequently attracted towards the negative electrode placed on another area 
of the body. 
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Figure 4.9 A schematic diagram illustrating the set-up of the electrode system 
on the skin surface. (a) Negatively charged electrode. (b) The iontophoresis 
chamber containing positively charged pharmacological substances with the 
attached electrode. (c) By applying a positive current to the electrode in (b), the 
positively charged pharmacological substances are repelled from the electrode 
and forced through the surface of the skin.  
Iontophoresis is an effective drug delivery system with many advantages. Since 
it is noninvasive, this technique avoids the risks of invasive procedures such as 
bleeding during intra-arterial puncture. It also prevents first pass metabolism by 
the liver therefore increases therapeutic efficacy of the pharmacological 
substance. In addition, iontophoresis minimises the risk of overdosing or 
underdosing as it provides a constant delivery of the drug. However, 
iontophoresis has its disadvantages (Turner et al., 2008). It is recognised that 
the exact quantity of drug such as ACH and SNP delivered in iontophoresis 
cannot be determined precisely, therefore, providing a less accurate blood flow 
response. In terms of side effects, the most commonly seen are minor reactions 
such as redness, itching and irritation of the skin surface exposed to the 
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iontophoretic delivery system. Rarely, some drugs may cause skin pigmentation 
after iontophoresis. Major side-effects are very rare.  
In clinical research, iontophoresis has been used in conjunction with laser 
Doppler flowmetry to study the role of the endothelium in the regulation of 
cutaneous blood flow. An example of such studies includes the assessment of 
skin microcirculation function in patients with Type I and II diabetes mellitus 
(Caballero et al., 1999, Lim et al., 1999, Khan et al., 2000, Beer et al., 2008). In 
these studies, cutaneous blood flow was assessed by measuring vascular 
responses to transdermal iontophoresis of acetylcholine (ACH) (endothelium-
dependent vasodilatation) and sodium nitroprusside (SNP) (endothelium-
independent vasodilatation). A reduction of vascular responses to both ACH 
and SNP were observed hence suggesting an impairment in the vasodilatory 
response (Caballero et al., 1999, Lim et al., 1999, Khan et al., 2000, Beer et al., 
2008).  
4.1.9 Post-occlusive reactive hyperaemia with full-field laser perfuser 
imager 
Reactive hyperaemia is defined as a transient compensatory increase in blood 
flow after a brief period of limb occlusion. In this condition, an increased shear 
stress against the blood vessel wall as a result of an increase in blood flow 
leads to the production of vasodilator metabolites, such as adenosine and NO, 
which dilates the microvasculature as a result of limb ischaemia.  
In research, PORH is used to assess the function of skin microcirculation. 
During this procedure, blood perfusion is measured at the forearm, before, 
during and after limb occlusion, therefore, allowing blood flow changes to be 
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recorded concurrently upon cuff released. When the FLPI is used to detect 
blood flow changes in response to PORH, the PORH tracing demonstrates a 
decrease in blood perfusion from the resting flux level to biological zero level on 
limb occlusion and after a period of time (normally 5 minutes), the occlusion is 
released and blood perfusion returns to the resting flux level but with a brief 
overshoot. The significance of this overshoot (peak response) has been shown 
to correlate with microcirculation function in some animal studies but generally 
the total area under the curve post 2 minutes recovery has been shown to 
correlate with vascular function in humans.  
The FLPI utilises a 780nm laser beam to provide real time microvascular 
perfusion that is proportional to the average velocity of red blood cells (Briers, 
2007). A charge-coupled device (CCD) video camera records the differences in 
motion of these red blood cells into speckled patterns. When there is fast blood 
flow, low contrast images are produced and inversely, when there is low blood 
flow, high contrast images are produced (Boas and Dunn, 2010). The contrast 
image is then processed and based on speckle contrast, a colour-coded image 
is produced. FLPI mainly measures superficial skin blood flow to a maximum 
depth of about 1mm.  
In healthy normal vasculature, blood flow rapidly increases above normal levels 
immediately after cuff release and is followed by a gradual drop in blood flow to 
the initial resting flux level. This so-called reactive hyperaemia occurs because 
during cuff occlusion, tissues become hypoxic and there is a buildup of 
vasodilatory mediators and metabolites which act to relax surrounding vascular 
smooth muscle cells, leading to vasodilatation of blood vessels (Kontos et al., 
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1965). In addition, decreased intravascular pressure in the arterioles due to 
arterial occlusion leads to myogenic mediated vasodilation which contributes to 
reactive hyperaemia (Lombard and Duling, 1977).   
Since NO bioavailability correlates with vascular function, it is important that a 
solely NO-dependent hyperaemic response is elicited as part of the 
assessment. Studies examining the contribution of NO in reactive hyperaemia, 
however, have yielded inconsistent findings with some showing that only 
immediately after arterial occlusion is the vasodilatory response most NO-
dependent (Raff et al., 2010, Tagawa et al., 1994) while others have 
demonstrated respectively the peak (Dakak et al., 1998, Yvonne-Tee et al., 
2005) and late phase (Tagawa et al., 1994, Joannides et al., 1995) of reactive 
hyperaemic depends most on NO bioavailability. In this project, I will investigate 
the relationship between the levels of KATP channels in blood and the different 
phases of the reactive hyperaemia response.  
4.2 Blood markers of vascular function 
In addition to the vascular function tests mentioned above, there exist blood 
biomarkers that are predictive of risk for CVD. However, full details will not be 
provided here as they are not within the scope of my thesis. They have been 
reviewed in other journals and some has been listed below. 
Table 4.3 Blood biomarkers predictive of CVD. 
Biomarker Articles 
Inflammatory markers:  
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 CRP Clearfield (2005); Blankenberg et 
al.(2010) 
 sICAM-1 Jager et al. (2000) 
 IL-6 Volpato et al. (2001); Kanda & 
Takahashi (2004); Danesh et al. 
(2008) 
 IL-18 Blankenberg et al. (2002); Jefferis et 
al. (2011) 
 SAA Johnson et al. (2004) 
 MPO Nicholls & Hazen (2005); Schindhelm 
et al. (2009) 
 sCD40L Schonbeck et al. (2001); Heeschen et 
al. (2003) 
 Oxidised LDL Meisinger et al. (2005) 
 GPX1 activity Blankenberg et al. (2003) 
 Homocysteine Homocysteine (2002) 
 Cystatin-C Koenig et al. (2005); Luc et al. (2006) 
 Natriuretic peptides Galvani et al. (2004); Kragelund 
(2005); Blankenberg et al. (2010); 50, 
86,91, 298-305 
Blood vulnerability  
(i) Hypercoagulable  
 Fibrinogen Fibrinogen (2005) 
 D-dimer Danesh et al. (2001) 
(ii) Decreased fibrinolysis  
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 TPA/PAI-1 Lowe et al. (2004) 
(iii) Increased coagulation factors  
 Von Willebrand factor Whincup et al. (2002) 
Endothelial function markers  
 E-selectin Gearing et al. (1992); Hwang et al. 
(1997) 
 VCAM-1 Richter et al. (2003) 
 ICAM-1 Hwang et al. (1997) 
CRP, C-reactive protein; sICAM, soluble intercellular adhesion molecule; IL, 
interleukin; SAA, serum amyloid A; MPO, myeloperoxidase; sCD40L, soluble 
CD40 ligand; GPX1, glutathione peroxidase; TPA, tissue plasminogen activator; 
PAI-1, plasminogen activator inhibitor-1. 
Having discussed the importance of early detection of subclinical CVD in 
preventing future CV events, there exists a need to identify novel markers which 
could potentially act as reliable surrogate indicators for vascular function. Up 
until now, vascular function has been assessed using different vascular function 
tests and by measuring levels of different blood biomarkers (Table 4.2). More 
recently, it has been recognised that KATP channels could potentially act as 
surrogates for vascular function as they play key roles in VSMCs in regulating 
peripheral vascular tone. In addition, there is a possibility that the levels of KATP 
channels in VSMCs are reflective of those found in blood.  
4.3 Aim and objectives 
The aim of this study, therefore, is: 
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• To investigate in normal healthy subjects whether the levels of KATP 
channel expressed in blood samples are related to the function of microvessels 
and macrovessels  
The objectives of this study is: 
• To determine whether there is a correlation between plasma levels of 
KATP channels and microvascular function, assessed using LDF with 
iontophoresis and post-occlusive reactive hyperaemia with FLPI, and 
macrovascular function assessed using FMD and pulse wave analysis 
The hypothesis of this study is there is a relationship between the levels of KATP 
channels in blood and vascular function. 
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CHAPTER 5 
Methods and materials 
5.1 Subjects 
Fifty young healthy volunteers (28 males, 22 females) aged between 19 and 27 
years were recruited for the study. All subjects were enrolled between 18th 
October 2010 and 31st October 2011. None of the subjects were smokers, used 
any medication or had a history of any symptomatic vascular disease(s).  
Subject characteristics are shown in Table 5.1. Ethnicity of subjects is 
summarised in Table 5.3. No formal power calculation has been performed to 
attain the sample size for this pilot study as it was carried out to obtain 
preliminary data that can be utilised for further planning of definitive studies. 
The study protocol was approved by the Tayside Committee on Medical 
Research Ethics and written informed consent was obtained from each subject 
before participation in the study. All fifty subjects attended at least one visit 
lasting up to three hours in which a blood sample was taken and vascular 
function was assessed using the tests discussed in the previous chapter. Blood 
samples were analysed for levels of KATP channels and markers of 
cardiovascular risk i.e. lipid profile. Vascular assessments were carried out in a 
blood flow laboratory at a temperature of 23 °C after 10 minutes of 
acclimatisation. Subjects were asked to refrain from any food and drink for at 
least 2 hours beforehand and also to refrain from physical activity for one day 
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before their visit. All subjects had their blood pressure, height and weight 
measured before vascular function tests were carried out.  
Table 5.1 Subject characteristics (n=50; 28 males, 22 females). Data are 
presented in mean ± SD. 
Subject characteristics n Mean ± SD 
Age (years) 50 22.0 ± 1.7 
Weight (kg) 50 65.2 ± 8.7 
Height (m) 50 1.7 ± 0.1 
BMI (kg/m2) 50 22.2 ± 2.6 
Brachial SBP (mmHg) 50 116 ± 12 
Brachial DBP (mmHg) 50 68 ± 8 
Ethnicity: 
White European males 12  
White European females 14  
South Asians males 7  
South Asians females 3  
Chinese males 9  
Chinese females 5  
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5. 2 Real time RT-PCR 
Five millilitres of venous blood was collected into a heparinised vacutainer from 
a vein in the upper arm of each subject. The vacutainer was placed in a sealed 
transport plastic bag containing ice and sent immediately to the laboratory for 
determination of the levels of KATP channels by real-time RT-PCR test. The time 
for transport took approximately 5-10 minutes. The real time RT-PCR was 
performed using well-established and characterised primers as described by 
Jovanović et. al. (2008) (Jovanović et al., 2008). In brief, once the blood 
samples are received by the laboratory technician, the process involved total 
ribonucleic acid (RNA) extraction from the human whole blood using TRIZOL 
reagent (Invitrogen, Paisley, UK) according to manufacturer’s instructions. The 
extracted RNA was further purified with RNeasy Mini Kit (Qiangen, Crawley, 
UK). The specific primers for human KATP channel genes (i.e. Kir6.1 and 
SUR2B) were designed using Beacon Designer 3.0 software and are described 
in Jovanović et al., 2008 (Jovanović et al., 2008) and Du et al., 2010 (Du et al., 
2010).The reverse transcriptase (RT) reaction was carried out with ImProm-II 
Reverse Transcriptase (Promega, Southampton, UK). A final volume of 20 μl of 
RT reaction containing 4μl of 5X buffer, 3mM MgCl2, 20U of RNasin® 
Ribonuclease inhibitor, 1U of ImProm-II reverse transcriptase, 0.5mM each of 
deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine 
triphosphate, and thymidine triphosphate, 0.5μg of oligo(dT), and 1μg of RNA 
was incubated at 42˚C for 1h, then inactivated at 70˚C for 15min. The resulting 
complementary deoxyribonucleic acid (cDNA) was used as a template for real-
time RT-PCR. A SYBR Green I system was used for the RT-PCR test and the 
25μl reaction mixture contained: 12.5μl of iQTM SYBR® Green Supermix (2X), 
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7.5nM each primers, 9μl of double distilled water, and 2 μl of cDNA. In principle, 
the conditions for thermal cycling were as follows: an initial denaturation at 95˚C 
for 3 minutes, 15s of annealing at 56˚C, and 30s of extension at 72˚C. The real-
time PCR was performed in the same wells of a 96-well plate in the iCycler 
iQTM MultiColor Real-time Detection System (Bio-Rad, Hercules, CA, USA). 
Following each cycle, data were collected and shown graphically (iCycler iQTM 
Real-time Detection System Software, version 3.0A, Bio-Rad).  
Primers were tested for their ability to produce no signal in negative controls by 
dimer formation and then with regard to the efficiency of the PCR reaction. 
Efficiency is evaluated by the slope of the regression curve obtained with 
several dilutions of the cDNA template. Melting curve analysis tested the 
specificity of primers. Threshold cycle values (Ct), PCR efficiency (examined by 
serially diluting the template cDNA and performing PCR under these conditions) 
and PCR specificity (by constructing the melting curve) were determined by the 
same software (Jovanović et al., 2008, Du et al., 2010). Each cDNA sample 
was duplicated; the corresponding no-RT mRNA sample was included as a 
negative control (blank) (Jovanović et al., 2008).  
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5.3 Assessment of microvascular function 
5.3.1 Laser Doppler flowmetry with acetylcholine iontophoresis 
LDF with iontophoresis was tested in 50 subjects (28 males, 22 females). 
Vascular function was assessed with the subjects lying supine on a bed with 
both arms comfortably beside the body (Figure 5.1).  The response to 
acetylcholine (ACH) iontophoresis in this test was measured on the volar 
surface of the right forearm. Flux recording was started after subjects 
acclimatised to the room temperature for 10 minutes, during which the forearm 
skin was prepared for measurements. The sites were cleaned by first using an 
adhesive tape to remove the superficial dead layer of the skin and washed 
gently with alcohol and then wiped gently dry.  The iontophoresis chamber 
(Moor Instruments Ltd., Axminster, UK) is a Perspex ring of diameter 20 mm 
with a wire electrode running round its inner surface, and this was fixed to the 
skin with adhesive tape. The hydrochloride salt of ACH (Miochol, Novartis), 
which is an endothelium-dependent vasodilator, was dissolved in de-ionised 
water to a concentration of 10 g/l (1%), and 2 ml of this solution was used to fill 
the chamber. The positive lead of a current source was connected to the 
chamber, and the negative lead attached to a conductive hydro-gel pad on the 
wrist, which served as the reference electrode. The subsequent changes in skin 
perfusion were assessed using laser Doppler imaging (moorLDI, Moor 
Instruments Ltd., Axminster, UK), which produces a colour image representing 
the distribution of skin blood flow (Figure 5.2). A 2mW helium-neon laser scans 
the surface of the skin, and light back scattered from moving erythrocytes is 
shifted in frequency by an amount proportional to their velocity. For each scan, 
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the computer builds up a colour-coded image representing skin blood perfusion 
over the scan area giving a relative measure called the laser Doppler flux 
(recorded in perfusion unit, P.U.). After two baseline recordings, ACH was 
delivered using an incremental anodal current of 10µA, 20µA and 50µA with 
iontophoretic stimulation repeated four times each. Two recordings were made 
at 100µA (Figure 5.2). For each dose response, the mean of the two highest 
stable flux values was calculated.  
  
Figure 5.1 Research set up for laser Doppler flowmetry with iontophoresis. 
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Figure 5.2 (a) A close-up view of the iontophoresis ACH drug chamber and the 
gel pad (reference electrode) on a subject’s forearm. (b) Colour-coded perfusion 
map showing increased skin perfusion after concurrent iontophoresis of ACH at 
increasing currents of 10µA, 20µA, 50µA and 100µA (Adapted from Turner et 
al., 2008). 
5.3.2 Post-occlusive reactive hyperaemia  
PORH was tested in 50 subjects (28 males, 22 females).  Vascular function was 
assessed with the subjects lying supine on a bed. The left forearm was rested 
at heart level and the skin microcirculation was measured at the volar aspect 
using a full field laser perfusion imager (moorFLPI, Moor Instruments Ltd., 
Axminster, UK) (Figure 5.3 (a)). A low-power laser beam was directed by the 
moorFLPI onto the skin surface of the forearm and a video frame of 10 images 
per second of blood perfusion in the skin microvasculature was obtained. 
Superficial microvascular perfusion was measured continuously from five 
individual regions of interest over an area of approximately 30cm2 and was 
recorded simultaneously in the form of a line graph. It is recognised that five 
regions are sufficient to be representative of the response by previous studies 
carried out in our department. Data collected from the five regions of interest 
were averaged to provide an overall response in arbitrary perfusion units. A 
blood pressure cuff was positioned over the upper arm and a baseline 
measurement of skin perfusion was obtained over 2 minutes. The cuff was then 
Gel 
pad 
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inflated to a suprasystolic pressure (200mmHg), thus, occluding any blood 
perfusion distal to the cuff for 5 minutes. After 5 minutes of occlusion, the cuff 
was deflated immediately resulting in an increase of blood through the skin 
microcirculation distal to the occlusion, termed PORH. The peak perfusion post-
cuff release was measured and the average perfusion over 2 minutes after cuff 
release was determined (i.e. the response over 2 minutes of recovery in 
reactive hyperaemia) (Figure 5.3(b)) 
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(a) 
 
(b) 
Figure 5.3 (a) Research setting of PORH with FLPI; (b) Tracing of PORH 
showing baseline, peak and average perfusion i.e. area under the curve, C. 
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5.4 Assessment of macrovascular function- brachial 
artery flow-mediated dilatation 
Brachial artery FMD was tested in 50 subjects (28 males, 22 females).  
Vascular function was assessed according to standard guidelines with the 
subjects lying on a bed in a supine position and their right arm rested at heart 
level (Figure 5.4(a)) (Coretti et al., 2002). Using high-resolution ultrasound 
imaging (Acuson Sequoia 512, Siemens Medical Solutions, Berkshire, UK), the 
brachial artery was imaged at the volar aspect above the antecubital fossa in 
the longitudinal plane. The ultrasound system is equipped with the vascular 
software for two dimensional imaging, a high-frequency vascular transducer, 
spectral and colour Doppler and an internal electrocardiogram (ECG) (to 
provide a trigger for the R wave, therefore, not a diagnostic ECG) (Coretti et al., 
2002). 
A snake-arm clamp was used to hold the ultrasound probe, therefore, allowing a 
stable image of the artery to be obtained throughout the study (Figure 5.4(b)). 
The ischaemic stimulus was produced by placing a blood pressure cuff above 
the antecubital fossa and inflating the cuff to suprasystolic pressure of around 
200mmHg for 5 minutes. After cuff release, reactive hyperaemia produces a 
transient increase in blood flow through the brachial artery, resulting in an 
increase in shear stress and dilatation of the brachial artery (Barac et al., 2007). 
Two dimensional images of the brachial artery were acquired at baseline for 1 
minute and post cuff release for 2 minutes. The precise diameter of the brachial 
artery on both occasions (baseline and post cuff released) were measured by 
automated edge-detection software (Figure 5.5). FMD was calculated as the 
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maximum percentage change in diameter post reactive hyperaemia relative to 
the baseline diameter (Hardie et al., 1997). 
(a) 
 
 
 
(b) 
 
 
 
 
Figure 5.4 (a) Brachial artery FMD in the research set up. (b) A close up view of 
the placement of the ultrasound probe and the blood pressure cuff on a 
subject’s arm. 
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Figure 5.5 Measurement of the diameter of the brachial artery (mm) using 
automated edge-detection software. The three circles are placed in the lumen of 
the brachial artery to permit correct alignment of the edge detection software ( 
the two outer circles can be adjusted depending on the angle of the region of 
interest of the artery). Once the correct position is obtained, the circles 
disappear and the diameter is being tracked by the lines on the edge of the 
vessel.  
5.5 Assessment of arterial stiffness- pulse wave 
analysis  
Subjects were rested in a supine position for at least 10 minutes. This is 
followed by triplicate blood pressure measurement using an automated blood 
pressure monitor (Omron 705 CPII). The degree of arterial stiffness was non-
invasively assessed using the AIx, which provides an estimation of systemic 
arterial and muscular stiffness, using the validated SphygmoCor pulse 
waveform analysis system (Scanmed Medical Instruments, Moreton-in-Marsh, 
UK). Peripheral pressure waveforms were recorded at the radial artery by 
applanation tonometry using a high fidelity micromanometer (Miller Instruments) 
(Figure 5.6). The peripheral waveform is calibrated against the systolic and 
diastolic blood pressure of the brachial artery as there is a negligible 
amplification of pressure between both sites. At least fifteen consecutive high 
Diameter of 
the brachial 
artery in 
millimetres 
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quality peripheral pressure waveform recordings were taken, from which an 
averaged peripheral pressure waveform is generated and a corresponding 
central (aortic) pressure waveform was derived automatically with the use of a 
validated generalised transfer function (Figure 5.7). From the averaged aortic 
pulse wave, the following parameters were calculated: 
o Aortic AIx (percentage), which is calculated as augmentation 
pressure divided by central pulse pressure multiply by 100. It is the 
difference between the first and second systolic peaks expressed as 
a percentage of the pulse pressure (Figure 5.8 and Figure 5.9). 
Larger values of AIx suggest increased PWV as a result of increased 
arterial stiffness and vice versa. Augmentation pressure represents 
the summation of the forward propagating incident wave generated 
by the left ventricular ejection and the backward propagating reflected 
wave.   
o Pulse pressure is the difference between the systolic and diastolic 
blood pressure (Figure 5.8) 
o Subendocardial viability ratio (SEVR) is an index of myocardial 
oxygen supply to demand ratio of the diastolic area under curve 
divided by the systolic area under curve (Figure 5.10) (Tsiachris et al., 
2012). It is a ratio of myocardial perfusion to myocardial contraction 
and serves as a non-invasive measure of myocardial perfusion 
relative to cardiac workload (Prince et al., 2010). 
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The SphygmoCor software incorporates an algorithm that normalises AIx to a 
heart rate of 75 beats per minutes (AIx@75) since AIx varies with heart rate 
(Sharman et al., 2009).  
 
Figure 5.6 Set up of PWA in the research study setting. The applanation 
tonometry is performed by placing the micromanometer over the radial artery. 
Fifteen consecutive high quality peripheral pressure waveform recordings were 
taken and can be seen as the images in the computer screen.  
Applanation 
tonometer 
(/micromano
meter) 
Tracing of 
radial 
pressure 
wave as 
detected by 
applanation 
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Figure 5.7 Recording of the peripheral (radial) artery applanation tonometry. 
The upper long panel shows the radial pressure waveform above the derived 
central pressure waveform. The upper right panel shows the superimposed 
radial waveforms, including the operator index, and the middle panel in green 
shows the quality control indices. The bottom right panel demonstrates a 
magnified derived central pressure waveform. Central pressure is 137/93 
mmHg. 
 
Figure 5.8 Central (aortic) pressure waveform. Systolic and diastolic pressures 
are the peak and trough of the waveform. Augmentation pressure is the 
additional pressure added to the forward wave by the reflected wave. The 
dicrotic notch denotes closure of the aortic valve and is utilised to calculate 
ejection duration. Time of return of the reflected wave (Tr) represents the time 
starting from the point of rise in the initial ejected pulse waveform to the onset of 
the reflected wave. (Adapted from Stoner et al., 2012 and Nelson et al., 2009) 
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Figure 5.9 Augmentation index (AIx) (%) is calculated as augmentation 
pressure (∆P) divided by pulse pressure (PP) multiply by 100 (Adapted from 
Lane et al., 2006) 
 
 
Figure 5.10 Subendocardial viability ratio (SEVR) (%) is the ratio of systolic 
area under the curve over diastolic area under the curve (Adapted from Mac-
Way et al., 2011) 
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5.6 Statistical analysis 
Pearson’s correlation was used to assess the relationship between the levels of 
KATP channels in blood and vascular function tests such as LDF with 
iontophoresis, pulse wave analysis, PORH and brachial FMD data. 
Furthermore, gender differences were investigated when looking at correlation 
between the levels of KATP channels in blood and vascular function tests. 
Statistical analyses were carried out using SPSS for Windows version 18.0 
(SPSS Inc.). Data are presented as mean ± SD and a probability value <0.05 
was considered statistically significant.  
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CHAPTER 6 
Results 
6.1 Kir6.1 mRNA, but not SUR2B mRNA, can been 
detected in human blood 
 
Real time RT-PCR was successfully completed in 40 of 50 subjects. Only Kir6.1 
mRNA was detected and the average threshold cycle (Ct) value for Kir6.1 was 
26.57±2.32 (n=40; Table 6.1). No signals corresponding to SUR2B mRNA were 
detected by real time RT-PCR. A higher average threshold cycle Ct value for 
Kir6.1 mRNA means less Kir6.1 mRNA levels were expressed in the blood. In 
simple terms, when there is a higher quantity of gene expression, i.e. Kir6.1 
mRNA, available, fewer cycles are needed (lower threshold cycle, Ct) for the 
same amount of time to reach the threshold line to be detected. Conversely, 
when there is a lower quantity of gene expression available, more cycles are 
needed (i.e. higher threshold cycle) for the same amount of time to reach the 
same threshold line. The threshold line is the point where the expressed gene is 
detected when it reaches a fluorescent intensity above background.  
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Table 6.1 KATP channels subunit levels measured (n=40; 23 males, 17 females). 
Data are presented in mean (±SD). 
KATP channels subunit 
levels  
N Mean (±SD) 
Kir6.1 (average) 40 26.57 (±2.32) 
SUR2B NIL NIL 
 
6.2 Kir6.1 mRNA levels in the blood correlate with 
brachial and aortic systolic blood pressure 
 
Ct values for Kir6.1 mRNA showed a significant positive correlation with both 
brachial (r=0.388, p=0.013, n=40; Figure 6.1) and aortic (r=0.364, p=0.021, 
n=40; Figure 6.2) systolic blood pressure. As Ct values is higher, the level of 
Kir6.1 mRNA is lower, so a positive correlation means that higher blood 
pressure is associated with lower expression of Kir6.1 in the blood.  
 
Figure 6.1 Ct values for Kir6.1 mRNA showed significant positive correlation 
with systolic blood pressure (r=0.388, p=0.013, n=40) for subjects.  
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Figure 6.2 Ct values for Kir6.1 mRNA showed significant positive correlation 
with aortic systolic blood pressure (r=0.364, p=0.021, n=40) for subjects. 
 
6.3 Correlations between Kir6.1 mRNA levels in blood 
and vascular function 
 
Vascular function was assessed using (i) LDF with iontophoresis, (ii) PORH 
using FLPI, (iii) FMD and (iv) PWA. FMD was used to assess the function of 
macrovessels. PWA was used to evaluate arterial stiffness, whereas the other 
two remaining tests were utilised to measure function of microvessels.  
In LDF with iontophoresis, there were incremental increase in vascular 
responses as the current increases (Table 6.2). 
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Table 6.2 Incremental increase in vascular responses as current increases in 
LDF with iontophoresis (n=50). 
 
Current in LDF with iontophoresis  Vascular responses (A.U.) 
Baseline blood perfusion, i.e. at 0µA 59.92 ± 28.94  
Blood perfusion at 10µA 203.78 ± 125.79  
Blood perfusion at 15µA 320.10 ± 159.02  
Blood perfusion at 20µA 373.79 ± 150.83  
Blood perfusion at 50µA 427.01 ± 148.15  
Blood perfusion at 100µA 441.47 ± 145.04 
 
PORH baseline skin perfusion was 65.86 ± 24.72 P.U. (n=50). Release of the 
cuff after 5 minutes occlusion resulted in a peak hyperaemia of 227.25 ± 64.21 
P.U. (n=50). The average reactive hyperaemia response over 2 minutes of 
recovery (PORH 2 minutes recovery) was 128.03 ± 39.74 P.U. (n=50).  
In FMD test, the baseline measurement of the brachial artery diameter was 3.55 
± 0.53 mm (n=50). Release of cuff after 5 minutes resulted in an increase of 
brachial artery diameter to a maximum of 3.83 ± 0.55 mm (n=50). Percentage 
change i.e. FMD was 7.98 ± 4.05 % (n=50).  
For PWA, the data collected included time to reflected wave (Tr) (time), SEVR 
(%), AIx and AIx@75 and they respectively are 153.24 ± 12.86, 170.02 ± 40.06, 
-0.64 ± 10.16 and -6.50 ± 11.82 (n=50).  
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The correlation between functional vascular response and Kir6.1 mRNA levels 
were assessed by looking into relationship between Ct for Kir6.1 mRNA levels 
and functional measures of vascular response. On bivariate analysis, the Ct 
values for Kir6.1 mRNA levels were significantly correlated with the average 
response to acetylcholine (ACH (ave) response) (r=-0.579, p˂0.001, n=40; 
Figure 6.4) of LDF with iontophoresis test. ACH (ave) response is the average 
of the blood perfusion recorded at 0µ, 10µA, 15µA, 20µA, 50µA and 100µA. As 
Ct values are lower, the level of Kir6.1 mRNA is higher, so a negative 
correlation means that lower vascular responses to iontophoresis are 
associated with lower expression of Kir6.1 in the blood. A positive significant 
correlation was noted between the Ct value for Kir6.1 mRNA and PORH 2 
minutes recovery PORH response (r=0.366, p=0.020, n=40; Figure 6.5) (this 
means higher PORH is associated with lower expression of Kir6.1 which is 
opposite to response to ACH. In contrast, no significant correlations were 
demonstrated between the Ct values for Kir6.1 mRNA and PWA parameters 
(augmentation index: r=0.080, p=0.266, n=40 (Figure 6.6); augmentation 
index@75: r=0.051, p=0.754, n=40; SEVR: r=-0.183, p=0.258, n=40 and Tr: 
r=0.243, p=0.130, n=40) as well as FMD (r=0.181, p=0.264, n=40; Figure 6.7). 
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Figure 6.3 Ct values for Kir6.1 mRNA were significantly correlated with the 
average response of acetylcholine (ACH (ave) response) of iontophoresis with 
laser Doppler flowmetry (r=-0.579, p˂0.001, n=40). 
 
 
Figure 6.4 Ct value for Kir6.1 mRNA were significantly correlated with PORH 2 
minutes recovery (r=0.366, p=0.020, n=40).  
77 
 
 
Figure 6.5 No correlation was noted between Ct values for Kir6.1 mRNA and 
AIx with levels (r=0.080, p=0.266, n=40). 
 
 
Figure 6.6 No correlation between the Ct values for Kir6.1 mRNA and FMD 
(r=0.181, p=0.264, n=40). 
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6.4 Correlation between Kir6.1 mRNA levels in the 
blood and lipid profile 
No correlations were noted between the Ct values for Kir6.1 mRNA and all lipid 
profile parameters except LDL (r=0.341, p=0.039, n=46; Figure 6.8). Data are 
presented in mean (±SD) (Table 6.3). 
Table 6.3 Lipid profile for 46 (26 males, 20 females) of 50 subjects.  
Lipid profile N Mean (±SD) r p value 
Total cholesterol 46 4.25 (±0.83) 0.228 0.175 
HDL 46 1.48 (±0.44) 0.020 0.907 
Triglycerides 46 1.17 (±0.65) 0.010 0.952 
LDL 46 3.86 (±1.02) 0.341 0.039 
Non-HDL 46 2.70 (±0.84) 0.249 0.137 
Total 
cholesterol/HDL  
46 3.05 (±1.15) 0.145 0.393 
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Figure 6.7 There was significant correlation between the Ct values for Kir6.1 
mRNA and LDL (r=0.341, p=0.039, n=46). 
 
6.5 Gender differences 
Gender had no influence on relationships between Ct values for Kir6.1 mRNA 
and vascular function apart from relationship between Ct values for Kir6.1 
mRNA and ACH (ave) response and PORH 2 minutes recovery.  In males, we 
observed a significant correlation between the Ct values for Kir6.1 mRNA and 
ACH (ave) response (r=-0.561, p=0.005, n=23; Figure 6.9) and PORH 2 
minutes recovery (r=0.418, p=0.047, n=23; Figure 6.10). In females, only 
significant correlation demonstrated was between the Ct values for Kir6.1 
mRNA and ACH (ave) response (r=-0.628, p=0.007, n=17; Figure 6.11). In 
males, significant correlations were noted between the Ct values for Kir6.1 
mRNA and both brachial (Figure 6.12) and aortic (Figure 6.13) systolic blood 
pressure (r=0.481, p=0.02, n=23 and r=0.417, p=0.048, n=23 respectively). This 
is not the case for females (brachial: r=0.294, p=0.253, n=17 and aortic: 
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r=0.339, p=0.183, n=17). No correlations were found between the Ct values for 
Kir6.1 mRNA and brachial as well as aortic diastolic blood pressure in either 
males or females. There was no statistical significant difference between males 
and females in the Ct values for Kir6.1 mRNA nor were there any significant 
differences in PORH, PWA and FMD. No significant correlations were found 
between the Ct values for Kir6.1 mRNA and PORH (Table 6.4), PWA (Table 
6.5) and FMD (Table 6.6) in either males or females except in males, the Ct 
values for Kir6.1 mRNA correlates with PORH 2 minutes recovery (r=0.418, 
0.047, n=23).  
 
Table 6.4 No correlation noted between Ct values for Kir6.1 mRNA and PORH 
in males and females except in males, the Ct values for Kir6.1 mRNA correlates 
with PORH 2 minutes recovery.  
 
 
PORH 
parameter (in 
males) 
r p n PORH 
parameter (in 
females) 
r p n 
Baseline 
perfusion 
0.326 0.129 23 Baseline 
perfusion 
0.240 0.354 17 
Peak PORH 0.076 0.732 23 Peak PORH -0.067 0.799 17 
PORH 2 
minutes 
recovery 
0.418 0.047 23 PORH 2 
minutes 
recovery 
0.226 0.384 17 
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Table 6.5 No correlation noted between Ct values for Kir6.1 mRNA and PWA in 
both males and females. 
 
PWA 
parameter (in 
males) 
r p n PWA 
parameter (in 
females) 
r p n 
Time to 
reflected wave 
(Tr) (time) 
0.302 0.161 23 Time to 
reflected wave 
(Tr) (time) 
0.124 0.634 17 
Subendocardial 
viability ratio 
(SEVR) (%) 
0.010 0.964 23 Subendocardial 
viability ratio 
(SEVR) (%) 
-0.365 0.150 17 
Aix 0.075 0.734 23 Aix 0.074 0.504 17 
AIx@75  -0.038 0.863 23 AIx@75  0.209 0.420 17 
 
 
 
Table 6.6 No correlation noted between Ct values for Kir6.1 mRNA and FMD in 
both males and females.  
 
FMD 
parameter (in 
males) 
R p n FMD parameter 
(in females) 
R p n 
Baseline 
measurement 
of the brachial 
artery (mm) 
0.131 0.552 23 Baseline 
measurement of 
the brachial 
artery (mm) 
-0.118 0.653 17 
Measurement 
of brachial 
artery after 5 
minutes cuff 
release (mm) 
0.197 0.367 23 Measurement of 
brachial artery 
after 5 minutes 
cuff release 
(mm) 
-0.014 0.956 17 
Percentage 
change i.e. 
FMD (%) 
0.229 0.293 23 Percentage 
change i.e. FMD 
(%) 
0.190 0.465 17 
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Figure 6.8 A significant correlation was noted between the Ct values for Kir6.1 
mRNA and ACH (ave) response in males (r=-0.561, p=0.005, n=23). 
 
 
 
Figure 6.9 The Ct values for Kir6.1 mRNA were correlated with PORH 2 
minutes recovery in males (r=0.418, 0.047, n=23).  
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Figure 6.10 The Ct values for Kir6.1 mRNA were correlated with ACH (ave) 
response in females (r=-0.628, p=0.007, n=17). 
 
 
 
Figure 6.11 The Ct values for Kir6.1 mRNA were correlated with brachial 
systolic blood pressure in males (r=0.481, p=0.02, n=23). 
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Figure 6.12 The Ct values for Kir6.1 mRNA correlate with aortic systolic blood 
pressure in males (r=0.417, p=0.048, n=23). 
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CHAPTER 7 
7.1 Discussion 
In the current study, the relationship between the levels of Kir6.1 mRNA 
subunits in blood with microvascular and macrovascular function of healthy 
normal subjects without cardiovascular disease was evaluated. It was 
demonstrated that Kir6.1, but not SUR2B, mRNA subunits can be detected in 
human blood. This finding is in keeping with previous animal studies which 
demonstrated expression of Kir6.1 mRNA subunits but not SUR subunits (Yasu 
et al., 2002). In addition, Yasu et. al (2002) have demonstrated fully functioning 
KATP channels in polymorphonuclear neutrophils (PMNLs) despite only detecting 
the pore-forming subunit, Kir6.1 or Kir6.2 mRNA subunit, using real time RT-
PCR. Since it is understood that expression of Kir alone does not result in fully 
functional KATP channels (Shyng et al., 1997), it is likely that an unknown SUR 
isoform is expressed in PMNLs. Another possibility, as suggested by Yasu et al 
(2002), is that there exist novel channels which mimic the activity of KATP 
channels in blood cells (Yasu et al., 2002). Since the primer used to detect 
human SUR2 subunit in this study is similar to those designed by Jovanovic and 
Du (unpublished) to detect SUR2 subunits in animal model, it could possibly 
mean that a different primer needs to be designed to be compatibility with 
human SUR2 subunit. However, up to date, no studies have designed 
compatible primer and experimented on human samples. Currently, the 
possible SUR variant has not yet been identified, however, based on the 
findings of this study, it is unlikely to be SUR2B, which is the known regulatory 
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subunit of KATP channel in VSMCs in the literature (Shi et al., 2007, Morrissey et 
al., 2005).  
A key issue raised in this study was whether a link could be established 
between the level of KATP channel subunits and vascular function. It is 
recognised that KATP channels play a central role in the regulation of vascular 
tone via various vasodilators and vasoconstrictors and hence in the regulation 
of blood pressure and blood flow. Therefore, it is possible that the degree of 
vasoreactivity of the vasculature, is dependent on the number of KATP channels 
in VSMCs i.e. increased number of activated KATP channels permit higher 
degree of blood vessel vasodilation, therefore, associated with increased blood 
flow i.e. better vascular function. Since only Kir6.1 mRNA subunits are detected, 
the question remains as to whether the level of Kir6.1 subunits are 
representative of the level of fully functional KATP channels in blood. It has been 
shown that the level of the least expressed KATP channel subunit can be 
representative of the level of KATP channels. Ranki et al (2001) and Jovanovic 
(2008) demonstrated that the level of the least expressed KATP channels subunit 
can be used as a proxy measure for the number of fully assembled-
sarcolemmal KATP channels in the heart and skeletal muscle (Ranki et al., 2001, 
Jovanović et al., 2008). Therefore, Kir6.1 mRNA subunit could be the rate 
limiting subunit which forms VSMC KATP channels and be a proxy measure for 
these channels. Another key issue raised in this study is can the level of KATP 
channels in blood be a direct reflection of those in the VSMCs? Definite proof is 
still lacking, however, it has been reported that since the expression of Kir6.2, 
another Kir6 isoform, is regulated by similar control elements in different tissues 
i.e cardiac, skeletal muscle and pancreas, the levels of Kir6.1 mRNA subunit 
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between blood and VSMCs could potentially be similar (Ashfield and Ashcroft, 
1998, Moritz et al., 2001).  
In this study, the levels of Kir6.1 mRNA subunit were measured using real time 
RT-PCR. Real time RT-PCR is a relatively new technique used to detect and 
quantify mRNA targets and has been shown to yield accurate and reliable 
results with significantly less quantities of blood required compared to any other 
techniques used to measure mRNA levels. During each cycle of PCR, this 
technique monitors the production of amplification products using fluorescent 
indicators. Since both amplification of DNA and detection of DNA levels occur 
simultaneously within one homogenous assay, this omits the need for post-PCR 
processing, hence reducing intra-operative error, thus, allowing higher 
reproducibility of results (Kennedy and Oswald, 2011).  
In this study, microvascular function was assessed by measuring LDF with 
iontophoresis and PORH while macrovessels was assessed using FMD. PWA 
was carried out to assess arterial stiffness. LDF with iontophoresis of ACH 
measures real-time microvascular flow and NO-dependent vasodilator reactivity 
in each subjects using chemical stimulus. On the other hand, PORH, which is 
dependent on shear stress (mechanical stimulus), measures microvascular flow 
in downstream resistance vessels. Hojs et. al. (2009) demonstrated that during 
LDF with ACH iontophoresis, ACH mediated vasodilatation was attenuated 
following introduction of glibenclamide, suggesting the important role of KATP 
channels in human cutaneous vasodilatation (Hojs et al., 2009). This is 
consistent with the findings of this study whereby a correlation was found 
between levels of Kir6.1 and ACH (ave) response. Cankar and Štrucl (2008) 
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and Banitt et al (1996) both shown that KATP channels contribute to vasodilation 
of human blood vessels during reactive hyperaemia particularly PORH 2 
minutes recovery but not peak PORH flow (Cankar and Štrucl, 2008, Banitt et 
al., 1996). These findings are in keeping with this study whereby a significant 
correlation was seen between the levels of Kir6.1 mRNA subunit and PORH 2 
minutes recovery but this was not seen with peak PORH blood flow.  
Based on the study’s hypothesis, the higher the levels of Kir6.1 mRNA subunit 
i.e. lower threshold cycles of Kir6.1, the better the vascular function. Although 
there was significant correlation between the threshold cycles of Kir6.1 levels 
and PORH 2 minutes recovery, unlike ACH (ave) response, the correlation 
between the former was a positive one i.e. the lower the Kir6.1 subunit levels, 
the better the vascular function. The reason for this observation is currently 
unknown but two possible conclusions can be drawn to explain the discrepancy 
between both tests: (i) this observation could be due to the involvement of 
different physiological mechanisms in these different vasodilator stimuli, (ii) 
paradoxical up-regulation of KATP channel expression which was only detected 
with PORH test but not with LDF with ACH iontophoresis. LDF with ACH 
iontophoresis depends on transdermal iontophoretic delivery of a chemical 
stimulus, i.e. ACH through the interstitium surrounding blood vessels, to elicit a 
blood flow response. A gradual increment in electric current allows blood flow to 
increase from baseline to reach a maximum plateau in response to ACH 
delivery transdermally. Unlike LDF with ACH iontophoresis, the stimulus for 
PORH is quite different compared with the former. PORH is elicited using 
mechanical stimulus, i.e. blood pressure cuff for occlusion, and is known to be 
partially dependent on myogenic-mediated vasodilation in downstream 
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resistance vessels. As described previously, reactive hyperaemia occurs after 
cuff released as a result of decreased vascular resistance due to a build-up of 
vasodilator metabolites intra-arterially which dilate arterioles. Hence, reactive 
hyperaemia does not occur in an incremental fashion as seen in LDF with ACH 
iontophoresis. Instead, PORH involves a rapid increase in blood flow from zero 
blood flow after blood pressure cuff release to reach peak flow in less than one 
minute before a gradual decrease in blood flow occurs until normal vascular 
tone is regained downstream. Although previous studies have shown that KATP 
channels contribute towards blood vessel vasodilation in both microvascular 
function tests, it is unclear whether the difference in the nature of stimulus could 
influence the level of expression of KATP channels in VSMCs. As for the second 
explanation, there is a possibility that VSMC KATP channels are up-regulated in 
conditions of reduced perfusion therefore acting as a compensatory mechanism 
to reduce vascular damage. This compensatory mechanism was demonstrated 
in cardiac muscle under metabolic stress by Bao et al. (2010) whereby an 
increased in surface density of KATP channels was seen leading to increase 
cellular resistance to hypoxia thus minimising cardiac damage (Bao et al., 
2010).  
In macrovessels, no correlation was found between levels of Kir6.1 subunits 
and FMD. Previous studies have shown that KATP channels play a more 
apparent role in resistance arteries and less so in conduit arteries. Wu et. al. 
demonstrated the involvement of KATP channels in resistance arteries in 
endotoxin-induced smooth muscle hyperpolarisation while Hodnett et. al. 
showed that in obese Zucker rats, arteriolar vasodilation was mediated by KATP 
channels (Wu et al., 2004, Hodnett et al., 2008). Therefore, it is possible that 
90 
 
the vasoregulatory mechanism in conduit arteries are not mediated by KATP 
channels. It is, therefore, not unreasonable to conclude that Kir6.1 could be an 
indicator for microvascular function but not macrovascular function since no 
correlation was seen between Kir6.1 levels and FMD. In addition, no correlation 
was found between the levels of Kir6.1 subunit and arterial stiffness indicating 
that Kir6.1 level is not a good marker of arterial stiffness. Currently, no other 
studies have examined the relationship between arterial stiffness and VSMC 
KATP channel levels.   
This study also showed a strong correlation between the threshold cycles of 
Kir6.1 levels with brachial and aortic systolic blood pressure i.e. the lower the 
expression of Kir6.1, the higher the systolic blood pressure. Since lower 
expression of Kir6.1 means poorer vascular function and that higher blood 
pressure is recognised to be proportionately related to increased CV events risk 
i.e. poorer vascular function, this finding was not unexpected (Prospective 
Studies Collaboration, 2003). Nonetheless, similar relationship was not seen 
between Kir6.1 levels and diastolic blood pressure. This observation could be 
explained by evidence which showed that systolic blood pressure increases 
steadily with age, whereas diastolic blood pressure increases until about age 50 
and then declines (Rockwood & Howlett, 2011).  
Although real-time RT-PCR represent a fast and effective method enabling 
quantification of mRNA levels with high sensitivity and precision, there are 
several challenges associated with this technique. These include careful 
isolation of RNA to ensure the integrity of the RNA itself and that the RNA 
template is free from contaminant. Contaminant such as DNA could contribute 
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to the final amplification signal thereby affecting the final product. Further 
studies are required to test reproducibility of Kir6.1 levels.  
In addition, this study showed that in males, significant correlations were found 
between Kir6.1 levels and ACH (ave) response as well as PORH 2 minutes 
recovery and both brachial and aortic systolic blood pressure. In females, only a 
correlation between Kir6.1 levels and ACH (ave) response was noted. This lack 
of correlation in females could be a result of hormonal differences or to a lesser 
extent due to a smaller sample size (23 males versus 17 females) compared to 
their male counterpart. It is recognised that hormones such as oestrogen are 
cardioprotective as they exert an antiatherogenic effect, mainly through the 
enhancement of nitric oxide by increasing endothelial nitric oxide synthase 
activity, on the vasculature (Ranki et al., 2001, Chambliss & Shaul, 2002). In 
premenopausal females, therefore, vasodilatory changes in blood vessels may 
be influenced by their menstrual phases. Since the different stages of menstrual 
cycle of female subjects were not taken into account, this could partially 
explained the differences observed.  
It is important to remember that this study is solely based on correlations and 
the above relationships do not necessarily prove causality. Further in depth 
statistical analysis such as explorative analyses, testing for normal distribution 
of the variables and multivariate analysis adjusting for any relevant confounders 
could have been performed. It is, therefore, difficult to robustly establish 
whether Kir6.1 level could potentially be a good indicator for vascular function.  
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7.2 Limitations 
Several limitations have been identified in the present study. It is understood 
that RNAses are present in all domains of life including atmospheric air. 
Therefore, whole blood RNA degradation could have occurred in heparinised 
blood tube prior to carrying out real-time RT PCR, possibly yielding inaccurate 
threshold cycles of mRNA subunits. This problem can be overcome by using 
special blood tubes such as Tempus or PAXgene Blood RNA Tube. These 
special blood tubes are costly but they collect, store and transport blood and 
stabilise intracellular RNA in a closed tube and allowing subsequent isolation 
and purification of intracellular RNA from whole blood for RT-PCR. It was 
suggested that since the promoter for Kir6.1 were similar for different tissues, 
there is a possibility that Kir6.1 levels were the same in both tissues. 
Nonetheless, it would be helpful if a direct relationship between the levels of 
Kir6.1 subunit in different tissues can be establish with specific test, yielding 
concrete data. This can be overcome by testing this relationship in animal 
models. Theoretically, rodent VSMCs can be harvested in vivo and VSMCs 
Kir6.1 subunit levels could be measured using laboratory techniques for 
comparison with the levels of Kir6.1 in blood of similar subject detected using 
real-time RT-PCR. Another limitation was this study was unable to identify the 
unknown SUR variance. It is recognised that both the pore-forming subunits 
and regulatory subunits are required to form fully-functioning KATP channels. 
Using real-time RT-PCR, this study has only identified Kir6.1 regulatory subunit 
from blood cells. In addition, subject sample size should be larger to investigate 
the relationship between Kir6.1 levels and gender differences. As this study has 
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only concentrated on normal healthy subjects, it would have benefited from the 
inclusion of older individuals or individuals with CVD, as it would have 
generated a wider spread of vascular function results, allowing the detection of 
meaningful correlations easier. 
7.3 Conclusion 
This present study has investigated the relationship between KATP channels in 
blood and vascular function. It was primarily aimed to investigate, in normal 
healthy subjects, whether the levels of Kir6.1 subunit expressed in blood 
samples are related to the function of both microvessels and macrovessles. In 
this study, it was demonstrated that Kir6.1 levels correlate with microvascular 
but not macrovascular function. Gender differences were also shown when 
correlating with the levels of Kir6.1 mRNA. In addition, this study found no 
correlation between Kir6.1 subunit levels and lipid profile as well as arterial 
stiffness. Despite the above findings, it appears unlikely that the levels of KATP 
channel has the potential to be a suitable and accurate surrogate of vascular 
function due to various factors as mentioned above in the ‘Discussion’ section. 
However, one would have to agree that it provides important pathophysiological 
insight which could act as the basis of future research.  
7.4 Recommendations for future research 
This research has raised some questions which require further investigations. It 
is recommended that further work needs to be undertaken to identify the 
unknown SUR subunit variance in VSMCs KATP channel.  In addition, further 
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studies in animal models could allow the determination of the levels of Kir6.1 
subunit between different tissues i.e. VSMCs and blood cells directly. This can 
be carried out as suggested in the section ‘7.2 Limitations’. More studies should 
also be carried out to investigate gender differences with larger sample size. 
Female subjects should be controlled for their menstrual cycle. Finally, further 
studies are required to investigate the reproducibility of Kir6.1 subunit levels 
with real-time RT PCR. Future studies could adapt the methods of this research 
project to yield data for comparison with the findings of this project. Once more 
answers are shed, further research could investigate the relationship between 
Kir6.1 levels and vascular function in patient population with vascular disease. 
Depending on these findings, there is scope for translational medicine to occur. 
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Appendix 1 Data collected for laser Doppler flowmetry with ACH iontophoresis 
These values are the average of four readings carried out at the same electrical current. ACH (ave) response is calculated by adding the flux 
reading for the baseline and flux reading recorded for the different electric current and divided by six. 
Subject ACH@0μA ACH@10μA ACH@15μA ACH@20μA ACH@50μA ACH@100μA 
1 94 361.5 500.5 553 538 530.5 
2 62.5 291 420 536.5 588.5 573.5 
3 56 302 395 395 384 365 
4 79 256.5 380 540.5 556.5 579.5 
5 58 248 535 581 426 560 
6 154.5 540.5 682.5 682.5 797.5 846.5 
7 59 366 505 519 559 536.5 
131 
 
8 58.5 158.5 360 451 580.5 602.5 
9 80 224.5 566.5 622.5 662 519 
10 54 208.5 424 451 480 466 
11 41.5 50 113.5 138 337.5 388.5 
12 60 186 286.5 293 281 320.5 
13 51 107 187 343 486.5 475.5 
14 53 158.5 273.5 366 493.5 517.5 
15 83 81.5 117.5 237.5 332 370.5 
16 47 79.5 193 260 383 372 
17 77.5 353.5 465.5 477 447.5 468 
132 
 
18 76.5 236.5 409.5 408.5 428 406 
19 49.5 255.5 347.5 278 353 406 
20 50 229.5 351.5 405.5 457.5 498.5 
21 53 82.5 141.5 175 192.5 241 
22 58 183 298.5 323 327.5 327.5 
23 56.5 122 324.5 399 413 426.5 
24 59.5 163.5 282 377 364.5 343 
25 46.5 266.5 375.5 379 366.5 363.5 
26 49 189 321 357.5 423 473.5 
27 55.5 117 324 400 465 511 
133 
 
28 52.5 271 495.5 556.5 583 612.5 
29 55.5 116 226.5 240.5 307.5 365 
30 67 218.5 450 498 541.5 505.5 
31 93 389.5 424 438.5 556 566.5 
32 95.5 102.5 130.5 241.5 356.5 374.5 
33 97 66.5 71.5 426 605 651 
34 103 70 70.5 67.5 101.5 116 
35 77 399 395.5 414 438.5 433.5 
36 70 72.5 80.5 90 148 164.5 
37 146 91 77 65 58 61.5 
134 
 
38 62 96.5 212 360.5 505.5 557 
39 53.5 198.5 199.5 190 234.5 229.5 
40 48 297 279 284 271 273.5 
41 11.4 627.5 745 706 665 573 
42 14 195.5 419 480.5 529.5 498.5 
43 5 88 183.5 185.5 208.5 241.5 
44 19.5 51 109 283.5 425 487.5 
45 20.5 126 279.5 360.5 549 667.5 
46 37.5 21.5 66 150.5 325 394 
47 32.5 149 327.5 390 427.5 431.5 
135 
 
48 51.5 321 402 404.5 422.5 436.5 
49 17.5 157.5 384.5 471.5 566.5 544 
50 44 245.5 396.5 436 402 401 
ACH@0μA means ACH flux reading at baseline 
ACH@10μA means ACH flux reading at 10μA etc 
All readings’ units in arbitrary units (A.U.) 
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Appendix 2 Data collected for post-occlusive reactive hyperaemia 
The five readings obtained from different sites in the forearm were averaged up to give the final reading which is used in data interpretation. 
Base 1 means baseline reading taken at rest in region one; base 2 means baseline reading taken at rest in region two etc. Peak 1 means 
reading that is taken at maximal blood perfusion post blood pressure cuff released in region one etc. Ave 1 means reading that is taken from 
the area under the curve 2 minutes post cuff released in region 1 
Subject 
Base 1 Base 
2 
Base 
3 
Base 
4 
Base 
5 
Peak 
1 
Peak 
2 
Peak 
3 
Peak 
4 
Peak 
5  
Ave 1 Ave 2 Ave 3 Ave 4 Ave 5 
1 76 72 79 78 76 233 223 234 261 246 125 107 130 141 128 
2 46 44 53 46 45 236 264 293 238 259 168 177 204 166 165 
3 51 49 48 49 52 197 202 172 183 222 112 105 115 116 115 
4 50 49 55 56 50 217 231 218 209 196 67 58 71 64 62 
5 67 60 71 70 65 298 288 326 306 298 142 131 156 156 141 
137 
 
6 50 47 55 54 50 356 317 351 318 336 101 88 105 102 87 
7 84 85 87 87 86 231 215 205 216 233 128 132 125 129 123 
8 139 118 146 107 136 347 329 327 283 298 210 190 193 170 181 
9 78 83 70 81 73 301 384 259 338 282 161 171 136 138 130 
10 41 36 38 34 37 174 169 167 154 166 87 82 83 77 81 
11 42 39 41 42 40 167 145 135 143 139 86 78 75 80 76 
12 52 51 47 50 57 240 254 251 237 251 119 119 125 119 131 
13 72 73 68 70 79 224 179 237 220 227 138 126 144 146 146 
14 49 44 48 44 42 229 187 209 186 191 96 86 97 86 82 
15 54 64 62 63 65 231 254 269 288 269 140 162 196 209 184 
138 
 
16 53 56 52 49 63 199 200 205 209 229 109 115 110 102 127 
17 61 64 62 60 57 257 281 260 283 292 95 100 98 96 88 
18 61 59 64 64 60 250 247 262 228 183 135 136 119 118 113 
19 44 45 49 47 43 130 153 112 126 132 83 85 88 92 77 
20 46 49 49 47 48 208 216 219 228 244 126 125 138 137 133 
21 54 56 56 56 52 140 161 153 149 151 70 82 69 77 77 
22 31 37 35 37 37 3 221 4 220 254 24 88 22 91 96 
23 46 45 41 44 43 132 137 114 119 147 92 97 90 92 97 
24 49 48 47 41 42 222 220 233 208 202 117 120 106 104 100 
25 32 38 37 33 38 110 185 166 178 200 93 117 107 111 126 
139 
 
26 44 45 44 49 47 220 263 211 234 227 114 121 120 125 111 
27 68 64 68 65 57 152 166 129 125 121 116 115 108 107 99 
28 52 61 59 65 60 308 306 290 289 325 112 108 119 112 126 
29 72 78 81 86 87 229 212 252 217 206 119 112 105 101 97 
30 82 84 82 84 85 230 213 235 199 239 156 150 167 149 162 
31 68 65 84 85 62 176 157 197 191 186 115 108 133 135 114 
32 77 72 89 86 76 242 242 283 290 262 122 119 110 123 113 
33 69 59 68 69 57 231 312 239 293 351 168 169 159 175 180 
34 105 89 110 109 96 368 332 349 325 329 203 184 203 196 191 
35 125 125 120 125 128 364 348 366 382 359 196 193 188 194 199 
140 
 
36 149 140 180 165 156 359 340 331 324 321 226 216 234 225 230 
37 88 95 89 82 90 282 277 282 242 247 209 204 194 179 193 
38 82 83 75 76 77 356 309 332 311 279 214 197 188 176 189 
39 96 84 87 86 85 303 279 313 293 280 228 212 206 184 198 
40 98 95 106 102 103 281 271 251 258 264 165 155 165 163 166 
41 71.8 67.7 63.4 66.7 60.5 247.5 274.7 219.3 251.5 221.9 124.1 125.4 122.5 122.5 105.9 
42 49 56.9 55.2 56.1 50.3 170 178.3 174 163.2 158.1 110.7 124.9 108.2 108 108.4 
43 64.3 66.8 64.3 66.4 63.3 138.9 150.8 138.1 145.9 134.9 101.3 110.3 103.3 105.3 102.7 
44 55.9 51.3 54.4 52.3 44.9 164.2 145 141.6 141.8 96.2 119.1 108.8 132.9 123.7 99 
45 61.7 65.2 71.3 77.6 73.2 201 226.7 222 262 275.3 126.1 149.8 138.8 161 164 
141 
 
46 50.8 53.6 57.5 52.4 48.3 138 168.4 164.8 176 155.8 99.3 119.6 122.4 129.6 114.7 
47 51.2 47.8 61.8 63.5 52.8 172.5 170.3 189.9 207 193.6 78.6 77.6 82.2 95.9 92.7 
48 57.6 60.3 65 66.9 63.8 165.4 160.8 208.2 205.8 190.4 131.4 126.5 143 150.8 149.5 
49 31.9 31 38.2 46.3 40.3 218.1 224.1 214.5 207.9 211.7 60.4 65.9 81.1 85.5 78.7 
50 54.5 54.1 59.5 66.8 57.3 172.8 181.9 168.3 188 168.5 113.2 115.2 117.7 129.9 113.9 
All units in perfusion units (P.U.) 
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Appendix 3 Data collected for flow-mediated dilatation 
Subjects Baseline diameter of brachial artery 
(mm) 
Postocclusion diameter of brachial artery 
(mm) 
FMD percentage change (%) 
1 3.69 4.00 8.40 
2 3.60 3.76 4.44 
3 3.78 3.86 2.12 
4 3.43 3.61 5.25 
5 3.18 3.34 5.03 
6 3.61 3.70 2.49 
7 2.76 2.97 7.60 
8 2.87 3.14 9.41 
143 
 
9 2.97 3.25 9.43 
10 3.86 4.12 6.74 
11 3.30 3.34 1.21 
12 3.20 3.42 6.88 
13 3.25 3.45 6.15 
14 3.40 3.69 8.53 
15 5.28 5.59 5.87 
16 3.26 3.61 10.74 
17 3.49 3.79 8.60 
18 3.18 3.42 7.55 
144 
 
19 3.45 3.60 4.35 
20 3.61 4.04 11.91 
21 4.13 4.60 11.38 
22 4.28 4.52 5.61 
23 3.23 3.49 8.05 
24 4.15 4.23 1.93 
25 3.91 4.27 9.21 
26 3.45 3.82 10.72 
27 2.63 2.98 13.31 
28 3.58 3.74 4.47 
145 
 
29 3.17 3.45 8.83 
30 3.28 3.40 3.66 
31 4.66 4.76 2.15 
32 2.92 3.32 13.70 
33 3.63 3.88 6.89 
34 3.22 3.70 14.91 
35 4.46 4.63 3.81 
36 3.86 3.97 2.85 
37 4.05 4.52 11.60 
38 3.28 3.72 13.41 
146 
 
39 4.40 4.95 12.50 
40 3.48 3.61 3.74 
41 3.13 3.51 12.14 
42 3.57 3.88 8.68 
43 3.04 3.26 7.24 
44 3.93 4.50 14.50 
45 4.06 4.51 11.08 
46 3.12 3.69 18.27 
47 3.12 3.58 14.74 
48 4.48 4.73 5.58 
147 
 
49 3.16 3.27 3.48 
50 3.15 3.39 7.62 
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Appendix 4 Data collected for pulse wave analysis 
Subject 
Brachial 
SBP 
(mmHg) 
Brachial 
DBP 
(mmHg) 
Brachial 
pulse 
pressure 
(mmHg) 
Aortic 
SBP 
(mmHg) 
Aortic 
DBP 
(mmHg) 
Aortic 
pulse 
pressure 
(mmHg) 
Tr (time) AIx  SEVR (%) Aix@75 
1 120.00 72.00 48.00 100.00 73.00 27.00 154.00 -5.00 148.00 -8.00 
2 108.00 61.00 41.00 88.00 62.00 26.00 139.00 -4.00 172.00 -12.00 
3 135.00 74.00 61.00 109.00 75.00 34.00 141.00 -6.00 186.00 -17.00 
4 104.00 72.00 32.00 91.00 73.00 18.00 154.00 -6.00 190.00 -12.00 
5 94.00 64.00 30.00 85.00 64.00 20.00 137.00 17.00 232.00 5.00 
6 122.00 68.00 54.00 100.00 68.00 32.00 157.00 -7.00 252.00 -19.00 
149 
 
7 127.00 84.00 43.00 111.00 85.00 26.00 142.00 9.00 123.00 11.00 
8 103.00 57.00 46.00 84.00 58.00 26.00 143.00 -12.00 151.00 -15.00 
9 111.00 72.00 39.00 96.00 73.00 23.00 165.00 -5.00 154.00 -9.00 
10 124.00 71.00 53.00 101.00 71.00 30.00 140.00 -2.00 139.00 -2.00 
11 111.00 63.00 48.00 91.00 64.00 27.00 141.00 3.00 171.00 -4.00 
12 109.00 63.00 46.00 89.00 64.00 25.00 138.00 -2.00 165.00 -6.00 
13 110.00 68.00 42.00 92.00 68.00 24.00 151.00 -19.00 181.00 -28.00 
14 107.00 73.00 34.00 96.00 74.00 22.00 141.00 14.00 145.00 10.00 
15 127.00 58.00 69.00 99.00 59.00 40.00 157.00 -9.00 233.00 -21.00 
16 119.00 75.00 44.00 101.00 76.00 25.00 157.00 2.00 169.00 -5.00 
150 
 
17 103.00 63.00 40.00 87.00 64.00 23.00 163.00 -10.00 179.00 -17.00 
18 106.00 72.00 34.00 92.00 73.00 19.00 156.00 -3.00 223.00 -14.00 
19 118.00 71.00 47.00 98.00 72.00 26.00 136.00 -3.00 154.00 -5.00 
20 87.00 52.00 35.00 73.00 52.00 21.00 175.00 -11.00 357.00 -26.00 
21 130.00 66.00 64.00 104.00 67.00 37.00 160.00 2.00 160.00 -5.00 
22 118.00 68.00 50.00 97.00 69.00 28.00 152.00 -7.00 179.00 -12.00 
23 121.00 80.00 41.00 105.00 81.00 24.00 144.00 3.00 139.00 3.00 
24 128.00 60.00 68.00 99.00 59.00 40.00 146.00 -9.00 138.00 -15.00 
25 106.00 62.00 44.00 88.00 63.00 25.00 159.00 -3.00 164.00 -7.00 
26 105.00 70.00 35.00 92.00 71.00 21.00 157.00 5.00 178.00 -2.00 
151 
 
27 99.00 59.00 40.00 85.00 60.00 25.00 195.00 10.00 163.00 4.00 
28 111.00 70.00 41.00 94.00 70.00 24.00 152.00 -21.00 189.00 -30.00 
29 92.00 60.00 32.00 81.00 61.00 20.00 133.00 10.00 121.00 14.00 
30 126.00 79.00 47.00 111.00 80.00 31.00 145.00 13.00 144.00 12.00 
31 124.00 69.00 55.00 101.00 70.00 31.00 152.00 -10.00 155.00 -15.00 
32 132.00 89.00 43.00 125.00 90.00 35.00 138.00 31.00 144.00 28.00 
33 124.00 72.00 52.00 103.00 73.00 30.00 157.00 -2.00 130.00 -2.00 
34 122.00 77.00 45.00 105.00 78.00 27.00 153.00 6.00 132.00 5.00 
35 130.00 67.00 63.00 104.00 68.00 36.00 158.00 -9.00 132.00 -12.00 
36 128.00 58.00 70.00 99.00 59.00 40.00 151.00 -4.00 177.00 -15.00 
152 
 
37 114.00 68.00 46.00 95.00 68.00 27.00 161.00 -4.00 175.00 -8.00 
38 114.00 59.00 55.00 95.00 60.00 35.00 164.00 6.00 128.00 7.00 
39 137.00 67.00 70.00 112.00 68.00 44.00 162.00 4.00 189.00 -8.00 
40 117.00 76.00 41.00 104.00 77.00 27.00 143.00 16.00 154.00 10.00 
41 127.00 83.00 44.00 110.00 84.00 26.00 145.00 5.00 143.00 3.00 
42 121.00 50.00 71.00 99.00 50.00 49.00 149.00 15.00 191.00 1.00 
43 111.00 70.00 41.00 94.00 71.00 23.00 156.00 -3.00 202.00 -15.00 
44 126.00 62.00 64.00 100.00 63.00 37.00 195.00 -1.00 200.00 -12.00 
45 120.00 58.00 62.00 94.00 59.00 35.00 152.00 -23.00 163.00 -29.00 
46 107.00 71.00 36.00 93.00 71.00 22.00 156.00 5.00 138.00 1.00 
153 
 
47 104.00 63.00 41.00 87.00 63.00 24.00 145.00 -7.00 152.00 -11.00 
48 132.00 80.00 52.00 111.00 81.00 30.00 159.00 -5.00 143.00 -6.00 
49 120.00 65.00 55.00 101.00 66.00 35.00 165.00 8.00 203.00 -4.00 
50 113.00 67.00 46.00 95.00 67.00 28.00 171.00 -4.00 151.00 -11.00 
Tr- time to reflected wave 
AIx- augmentation index 
SEVR- subendocardial viability ratio 
AIx@75- augmentation index at 75 beats per minutes 
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Appendix 5 Data collected for levels of Kir6.1 
Subjects Threshold cyles of Kir6.1 Subjects Threshold cyles of Kir6.1 
1 23.70 26 23.90 
2 32.10 27 24.50 
3 25.20 28 23.30 
4 - 29 24.50 
5 26.00 30 23.10 
6 24.50 31 - 
7 26.90 32 24.60 
8 - 33 - 
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9 - 34 - 
10 26.80 35 23.80 
11 25.70 36 26.50 
12 26.80 37 - 
13 22.70 38 - 
14 - 39 26.70 
15 - 40 26.95 
16 25.50 41 27.85 
17 29.00 42 28.60 
18 27.75 43 27.85 
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19 30.70 44 27.35 
20 29.60 45 29.20 
21 23.25 46 25.90 
22 28.75 47 30.45 
23 27.15 48 29.55 
24 25.45 49 26.65 
25 25.10 50 28.80 
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Appendix 6 Data collected for lipid profile 
Subject 
Total cholesterol HDL Triglycerides LDL Non-HDL Total 
cholesterol/HDL 
1 3.98 1.50 0.81 2.12 2.49 2.70 
2 3.02 1.45 0.51 1.33 1.57 2.10 
3 3.91 1.25 0.81 2.29 2.67 3.10 
4 4.55 1.91 1.22 2.08 2.63 2.40 
5 3.85 1.38 0.69 2.16 2.47 2.80 
6 2.87 1.46 0.51 0.00 1.41 2.00 
7 4.19 1.54 0.75 2.31 2.65 2.70 
8 2.97 0.60 0.51 0.00 2.37 5.00 
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9 3.28 1.40 1.32 1.27 1.88 2.30 
10 5.47 1.58 1.97 2.99 3.89 3.50 
11 3.84 1.28 0.93 2.14 2.57 3.00 
12 5.31 0.69 1.65 3.86 4.61 7.70 
13 2.86 0.97 1.20 1.34 1.89 3.00 
14 4.21 0.94 3.31 1.75 3.26 4.50 
15 5.68 2.59 1.06 0.00 0.00 0.00 
16 5.14 2.08 1.41 2.41 3.06 2.50 
17 4.92 1.54 1.51 2.69 3.38 3.20 
18 - - - - - - 
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19 3.18 0.97 1.06 1.73 2.21 3.30 
20 - - - - - - 
21 3.70 1.99 0.74 1.37 1.71 1.90 
22 3.66 1.31 0.68 2.03 2.35 2.80 
23 5.95 1.58 1.88 3.51 4.37 3.80 
24 4.33 1.74 0.66 2.29 2.60 2.50 
25 3.96 1.50 0.51 0.00 2.46 2.46 
26 3.68 0.93 0.51 0.00 2.76 4.00 
27 4.55 2.14 0.51 0.00 2.41 2.10 
28 3.89 1.56 0.84 1.94 2.33 2.50 
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29 4.28 0.87 3.00 2.03 3.41 4.90 
30 3.44 1.51 1.21 1.38 1.93 2.30 
31 4.05 1.73 0.73 1.99 2.32 2.30 
32 5.71 1.40 2.29 3.26 4.31 4.10 
33 4.69 2.25 0.51 0.00 2.44 2.10 
34 4.11 0.96 1.64 2.40 3.15 4.30 
35 3.39 0.83 1.21 2.01 2.57 4.10 
36 3.93 1.38 1.47 1.87 2.55 2.80 
37 - - - - - - 
38 - - - - - - 
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39 6.06 1.83 1.33 3.62 4.23 3.30 
40 5.02 2.03 0.72 2.66 2.99 2.50 
41 4.62 1.36 1.14 2.73 3.25 3.40 
42 5.42 2.02 1.67 2.64 3.40 2.70 
43 3.92 1.28 0.83 2.26 2.64 3.10 
44 4.03 1.35 1.05 2.19 2.68 3.00 
45 4.94 1.81 0.92 2.71 3.14 2.70 
46 5.02 1.21 1.47 3.14 3.81 4.20 
47 4.07 2.01 2.54 0.90 2.06 2.00 
48 4.09 0.99 0.90 2.68 3.10 4.10 
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49 3.73 1.54 0.54 1.94 2.18 2.40 
50 3.95 1.72 0.95 1.80 2.23 2.30 
 
 
 
